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ABSTRACT
Melanoma is a malignant skin cancer with high metastatic potential. The 
number of melanoma cases worldwide is increasing faster than any other cancer. 
The prognosis is bad in the advanced stages of the disease due to resistance to 
conventional  anti-cancer  treatments.  Patients  diagnosed  with  advanced  stage 
melanoma continue to pose a significant challenge for clinicians. Although many 
therapeutic regimens for metastatic melanoma have been tested, very few achieve 
response rates greater than 25%. There is much hope for targeted therapies and 
promising agents include those that act on apoptosis-regulating molecules. Very 
recently, we have identified that an immunophilin, namely FK506 binding protein 
(FKBP)  51 controls  response of  melanoma to DNA damaging  agents,  such as 
anthracyclines compounds. The aim of this study was to investigate the possible 
role of FKBP51 in the control of response to ionizing radiation (IR) in malignant 
melanoma.  FKBP51-silenced  cells  showed  reduced  clonogenic  potential  after 
irradiation compared with non-silenced cells. After IR, we observed apoptosis in 
FKBP51-silenced cells and autophagy in non-silenced cells. FKBP51 was required 
for  the  activation  of  Rx-induced  NF-B,  which  in  turn  inhibited  apoptosis  by 
stimulating  X-linked  inhibitor  of  apoptosis  protein  and  promoting  authophagy-
mediated  Bax degradation.  Using a  tumor-xenograft  mouse  model,  the  in  vivo 
pretreatment  of  tumors  with FKBP51-siRNA provoked massive  apoptosis  after 
irradiation.  Immunohistochemical  analysis  of  10  normal  skin  samples  and  80 
malignant cutaneous melanomas showed that FKBP51 is a marker of melanocyte 
malignancy,  correlating  with  vertical  growth  phase  and  lesion  thickness. 
Moreover,  we provided  evidence  that  FKBP51 targeting  radiosensitizes  cancer 
stem/initiating  cells.  Finally,  we  expanded  the  study  to  other  types  of  cancer, 
including ovarian, pancreatic, prostate, colon, breast and lung cancer and found a 
strong correlation between the protein expression and malignity  of the tumoral 
lesions. In  conclusion,  our  study  identifies  a  possible  molecular  target  for 
radiosensitizing therapeutic strategies against malignant melanoma and a potential 
novel tumoral biomarker.
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BACKGROUND
FK506 Binding Proteins (FKBPs)
FKBP51  is  a  member  of  the  FK506  binding  proteins  (FKBP),  these 
proteins,  together  with  cyclophilins  (Cyp),  belong  to  the  family  protein  of 
immunophilins (Dornan J et al. 2003).  FKBP derive their name by the ability 
to bind immunosuppressant agents like rapamycin and FK506 (Fischer G et 
Aumüller T. 2003). In addition to the capacity to bind to immunosuppressant 
drugs, immunophilins have another distinguishing property, namely peptidyl-
prolyl  cis-trans  isomerase  activity  (PPIase)  catalyzing  the  isomerization  of 
peptidylprolyl imide bonds, from cis to trans, in protein substrates (Dornan J et 
al. 2003; Fischer G et al.2003) (Fig.1).
Fig.1.  Peptidyl-prolyl  cis-trans  isomerase  activity  (PPIase).  Immunophilins 
catalyze  the  isomerization  of  peptidyl-prolyl  imide  bonds,  from  cis  to  trans,  in  protein 
substrate.  This  activity  can  influence  the  function  of  different  proteins,  especially  some 
kinases, making them more stable and improving their activity. Indeed, the straighter shape of 
the trans isomer leads to hydrogen intermolecular forces that make the isomer more stable,  
than the cis isomers.
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In humans, at least 15 FKBPs have been identified and named to reflect their 
molecular  weights  (Somarelli  JA  et  al.  2008).  Family  members  of  this 
ubiquitous enzyme class are found in abundance in virtually all organisms and 
subcellular compartments.  Their  amino acid sequences are highly conserved 
phylogenetically (Fischer G and Aumüller T. 2003). Organisms express many 
members  of  each  family  that  encompass  one  or  more  PPIase  domain, 
complemented with other functional polypeptide segments (Fig.2). 
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Fig.2. FKBPs domains. FKBP12 is the prototype FKBP containing only a single FK506-
binding domain (FKBD) comprising 108 amino acids. FKBPs show structural similarity to that 
of FKBP12, but possess further domains involved in protein-protein interaction or tetratrico  
peptide  repeat  (TPR)  motifs,  nuclear  signaling,  calcium  binding,  protein  trafficking,  and 
ATP/GTP-binding sequences, explaining the wide variety of cellular functions these proteins 
exhibit.
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These  domains  include  tetratricopeptide  repeat  motifs  involved  in  protein-
protein  interaction,  EF-hand calcium-binding  domain  containing  helix-loop-
helix topology in which Ca2+ ions are coordinated within the loop, nucleic acid 
binding  regions,  transmembrane  domain,  and  nuclear  localization  and 
endoplasmic reticulum signal sequences. These domains enable such proteins 
to  perform  a  wide  variety  of  cellular  functions,  including  protein  folding, 
improvement  of  kinase  performance,  receptor  signaling,  protein  trafficking, 
and transcription  (Dornan J  et  al.  2003;  Fischer  G and Aumüller  T.  2003; 
Somarelli JA et al. 2008).
FKBP51 and its functions
Immune system
FKBP51 is an immunophilin physiologically expressed in T lymphocytes. 
This protein is capable of immunosuppression, mediated by calcineurin (CaN) 
inhibition,  when complexed to FK506 (Baughman G et al.  1995). CaN is a 
Ca2+/calmodulin-dependent  serine-threonine  phosphatase  that  regulates  the 
clonal expansion of T cells, after stimulation by an antigen, through activation 
of the nuclear factors of activated T lymphocytes (NFAT). NFAT proteins are 
phosphorylated and reside in the cytoplasm in resting cells; upon stimulation, 
they are dephosphorylated by CaN, translocated to the nucleus, and become 
transcriptionally  active  (Hogan  PG  et  al.  2003).  The  NFAT  group  of 
transcription factors regulates production of interleukin (IL) 2 and a number of 
T cell specific activators, leading to immune response. 
Glucocorticoid response
FKBP51 is  also  part  of  the  glucocorticoid  receptor  (GR)  complex  and 
regulates  the  response  to  these  hormones.  Glucocorticoids  up-regulate  the 
FKBP51  gene,  whose  product  in  turn  reduces  response  to  glucocorticoids, 
thereby  providing  a  mechanism  for  desensitization  of  cells  after  an  initial 
exposure to  the hormone (Cheung J and Smith  DF.  2000).  Indeed,  cortisol 
insensitivity is facilitated by a constitutive overexpression of FKBP51 (Cheung 
J and Smith DF. 2000). Increased intracellular FKBP51 protein expression is 
associated  with  particular  single  nucleotide  mutations  of  the  FKBP51 gene 
(Binder  EB  et  al.  2004).  This  condition  triggers  adaptive  changes  in  the 
glucocorticoid  receptor  and  provokes  alteration  of  the  stress  hormone-
regulating  hypothalamic-pituitary-adrenal  axis,  with  implications  for  the 
psychic sphere (Binder EB et al. 2004). Genetic mutations leading to FKBP51 
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hyperexpression have been correlated with major depressive disorders (Binder 
EB et al. 2004).
Nervous system
In  the  nervous  system,  FKBP51  prevents  clearance  of  tau  protein  by 
regulating its phosphorylation status (Jinwal UK et al. 2010). Tau is a highly 
soluble microtubule-associated protein, particularly abundant in neurons, that 
is important for the stability of axonal microtubules (Goedert M et al. 2000). 
FKBP51-mediated isomerization of tau reduces its phosphorylation pattern and 
prevents its clearance, which results in microtubule stabilization (Jinwal UK et 
al. 2010). By contrast, tau hyperphosphorylation leads to its abnormal buildup, 
with self-assembly of tangles of paired helical filaments and straight filaments 
(Alonso  A  et  al.  2001).  Accumulation  of  these  aggregates,  which  have  a 
neurotoxic  effect,  is  a  common  feature  for  a  group  of  diseases  termed 
tauopathies,  the most  common being Alzheimer's  disease (Goedert  M et al. 
2000; Alonso A et al. 2001). 
NF-B activation
FKBP51 isomerase activity is important for the enzymatic function of the 
inhibitor  B  kinase  (IKK)   (Boumeester  T  et  al.  2004).  The  NF-B 
transcription  complex  belongs  to  the  Rel  family,  which  comprises  five 
mammalian  Rel/NF-B  proteins:  RelA  (p65),  c-Rel,  RelB,  NF-B1 
(p50/p105), and NF-B2 (p52/100) (Ghosh S et al. 1998). The activity of NF-
B is controlled by cytoplasmic shuttling to the nucleus in response to cell 
stimulation. The NF-B dimers containing RelA or c-Rel are retained in the 
cytoplasm through interaction with inhibitors (IBs) (Baldwin AS Jr. 1996). In 
the canonical  pathway of NF-B activation,  IKK forms with IKK and a 
regulatory subunit  of IKK,  namely NEMO, the IKK kinase complex,  that 
mediates the phosphorylation of IB proteins in response to various stimuli 
(Baldwin AS Jr. 1996).  Phosphorylated IBs create a recognition signal for 
ubiquitinating  enzymes,  which  mark  IBs  for  rapid  26S  proteasomal 
degradation (Baldwin AS Jr. 1996). This process allows p50/RelA dimers to 
translocate  to  the  nucleus,  where  they stimulate  the  expression  of  multiple 
target genes involved in immune response, inflammation, cell survival, anti-
apoptosis,  and  cancerogenesis  (Ghosh  S  et  al.1998;  Karin  M et  al.  2002). 
IKK also works independent of the IKK complex.  This occurs, for instance, 
in  the  alternative  NF-B pathway,  which  results  in  activation  of  p52/RelB 
heterodimers  (Xiao  G  et  al.  2001).   In  this  pathway,  IKK requires  an 
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upstream  kinase,  namely  NF-B-inducing  kinase  (NIK),  and  induces 
phosphorylation  of  p100  to  produce  mature  p52  (Xiao  G  et  al.  2001). 
Furthermore,  active  IKK phosphorylates  CREB-binding  protein  (CBP)  at 
serine 1482 and serine 1386. Such phosphorylation enhances NF-B-mediated 
gene  expression  and  suppresses  p53-mediated  gene  expression,  thereby 
promoting cell proliferation and tumor growth (Huang WC et al. 2007) (Fig.3).
 
Fig.3. Schematic representation of the NF-B activation pathways, namely 
canonical-, atypical- and non canonical- pathway (see text).
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Role of FKBP51 in cell growth and malignant transformation
FKBP51 was first cloned in the mouse where it appeared to be restricted to 
T  lymphocytes  (Baugman  G  et  al.  1995).  Subsequent  studies  in  humans 
confirmed that FKBP51 is abundantly expressed in T lymphocytes and is also 
expressed in several other  tissues; although,  it  is not a uniform distribution 
(Baugman  G  et  al.  1997).  There  is  increasing  evidence  that  enhanced 
expression of FKBP51 sustains cell survival and growth in both non neoplastic 
and neoplastic conditions. The FKBP51 homolog in Arabidopsis, PAS-1, plays 
a critical role in the growth and development of this organism (Vittorioso P et 
al. 1998). In mammals, FKBP51 has a specialized role during cell division and 
is preferentially expressed in mitotically active cells, in the very early phases 
of differentiation (Liu TM et al. 2007; Menicanin et al. 2009; Yeh WC et al. 
1995).  FKBP51  is  among  the  top  candidates  genes  expressed  during  early 
mesenchymal  differentiation  into  the  three  mesodermal  lineages  namely 
osteogenesis/chondrogenesis/adipogenesis  (Menicanin  et  al.  2009).  At  this 
stage, FKBP51 is co-expressed with ZNF145 (Menicanin et al. 2009). ZNF145 
is a member of the Krueppel C2H2-type zinc-finger protein family, it encodes 
a zinc finger transcription factor that interacts with a histone deacetylase and is 
involved in cell cycle progression (Menicanin et al. 2009; Yeh WC et al. 1995; 
Zhang et al.  1999). Abnormal rearrangement  of ZNF145, due chromosomal 
translocation  t(11;17),  causes  acute  promyelocytic  leukemia  (Zhang  et  al. 
1999).
Myeloproliferative disorders
The concept that FKBP51 is an essential factor for cell proliferation is also 
supported by studies on myeloproliferative disorders (Komura E et al. 2003; 
Komura E et al. 2005; Giraudier S et al. 2002). FKBP51 is overexpressed in 
idiopathic myelofibrosis (Komura E et al. 2003), a chronic myeloproliferative 
disorder  characterized  by  megakaryocyte  hyperplasia  and  bone  marrow 
fibrosis.  Overexpression  of  FKBP51  in  this  disorder  regulates  the  growth 
factor independence of megakaryocyte progenitors and induces an apoptotic 
resistance  to  cytokine  deprivation  mediated  by  the  JAK/STAT5  pathway 
(Komura E et al. 2003). It has been shown that STAT5 is dephosphorylated on 
tyrosine  residues  more  slowly in an FKBP51-overexpressing cell  line.  This 
condition sustains cell survival mechanisms, as suggested by the pro-apoptotic 
effect of a dominant negative variant of STAT5. The high pSTAT5 levels are, 
in  turn,  sustained  by  persistent  JAK2  phosphorylation.  The  spontaneously 
megakaryocyte  growth  was  abolished  by  the  JAK2  inhibitor  AG490. 
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Furthermore, FKBP51 overexpression promotes fibrosis, that is mediated by 
upregulation of TGF- synthesis (Komura E et al. 2005).
Glioma
Enhanced FKBP51 expression is associated with apoptosis resistance and 
enhanced proliferation in gliomas (Jiang W et al. 2008). A study of specimens 
from  192  patients,  including  glioblastoma  multiforme,  oligodendrogliomas, 
astrocytomas,  and  mixed  gliomas,  showed  the  FKBP51  expression  level 
correlated with grading (Jiang W et al. 2008). The study of patient survival 
showed that the expression of FKBP51 correlated with overall glioblastoma 
patient  survival  rates;  that  is,  the  glioblastoma patients  with  high  levels  of 
FKBP51 had shorter survival than those with intermediate levels (Jiang W et 
al. 2008). Moreover, using both hyperexpression and knock-down approaches, 
it  was  shown  that  FKBP51  proliferative  and  anti-apoptotic  properties  in 
gliomas were mediated by NF-B activation (Jiang W et al. 2008). 
Prostate cancer
In prostate cancer, FKBP51 is upregulated in association with cyclophilin 
Cyp40 (Periyasamy S et al. 2010).  In androgen-dependent tumor cell lines of 
prostate  cancer,  FKBP51  hyperexpression  increased  androgen  receptor 
transcriptional  activity  in  the  presence  and absence  of  androgens;  whereas, 
knockdown  of  FKBP51  dramatically  decreased  androgen  dependent  gene 
transcription  and  proliferation.  In  androgen-independent  prostate  cancer, 
FKBP51  was  also  hyperexpressed  (Periyasamy  S  et  al.  2010).  Most 
intriguingly, a very recent paper implicates IKK in the androgen independent 
growth of prostate cancer (Ammirante M et al. 2010).
FKBP51 is an important molecular determinant in the anticancer  
activity of rapamycin
In  a  previous  study  our  laboratory  provided  evidence  supporting  the 
involvement  of  FKBP51  in  the  resistance  to  cancer  therapies  through 
mechanistic studies of the antitumor activity of rapamycin (Avellino R et al. 
2005;  Romano  MF  et  al.  2004).   Rapamycin  is  a  conventional 
immunosuppressant  agent  with  anticancer  properties  (Sabatini  DM.  2006). 
Both immunosuppression and anticancer effects of rapamycin are classically 
ascribed to inhibition of the mammalian target of rapamycin (mTOR) (Sabatini 
DM 2006), which is the core of an evolutionarily conserved signaling pathway 
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that controls the cell cycle in response to changing nutrient levels (Schmelzle T 
and Hall MN. 2000). The rapamycin/FKBP complex interacts with the FKBP-
rapamycin binding domain in mTOR, adjacent to the catalytic kinase domain, 
and blocks its function (Choi J et al. 1994). mTOR is a member of the ataxia-
telangiectasia-mutated (ATM) family of kinases that functions as a checkpoint 
for nutritional status in G1 (Brown EJ et al. 1994). It is a downstream protein 
in  the phosphatidylinositol  3  kinase  (PI3k),  protein  kinase  B (PkB or  Akt) 
signaling pathway (Burgering BM and Coffer PJ. 1995; Gao X and Pan D. 
2001). Many genomic aberrations in human cancers result in activation of this 
pathway, which alters the control of survival and leads to defective apoptosis 
(Hennessy  BT  et  al.  2005).  Generally,  such  genomic  aberrations  involve 
deletions of the tumor suppressor gene PTEN, the inositol 3-phosphatase and 
tensin  homologue,  which  dephosphorylates  phosphoinositides  at  the  D3 
position,  thereby terminating  the  PI3k/Akt  cascade  (Wu X et  al.  1998).  A 
number of rapamycin analogs have been developed over recent years and have 
shown antitumor activity across a variety of human cancers in clinical trials 
(Sabatini DM. 2006).
However,  our  recent  studies  identify  FKBP51  as  an  additional  important 
molecular determinant of the drug’s anticancer activity (Avellino R et al. 2005; 
Romano  MF  et  al.  2004;  Jiang  W  et  al.  2008).  In  a  study  conducted  in 
melanoma, a tumor in which PTEN is often mutated (Wu H et al. 2003), we 
found  that  rapamycin  markedly  enhanced  doxorubicin-induced  apoptosis 
(Avellino  R et  al.  2005).  However,  contrary  to  expectations,  the  apoptosis 
sensitizing effect of rapamycin appeared to be independent of blockage of the 
PI3k/Akt/mTOR pathway and was instead associated with inhibition of NF-B 
signalling. Rapamycin, but not wortmannin, a PI3k inhibitor, induced a block 
of the IKK kinase phosphorylating ability (Avellino R et al. 2005). The effect 
of  rapamycin  on  NF-B  was  reproduced  using  FKBP51  siRNA,  which 
depleted the cell  of this protein. In accordance,  the NF-B regulated genes, 
Bcl-2 (Catz SD and Johnson JL. 2001) and c-IAP1 (Wu MX et al. 1998), were 
decreased;  these  genes  have  been  implicated  in  tumor  cell  resistance  to 
doxorubicin (Lopez de Menezes DE et al. 2003; Vaziri SA et al. 2003). The 
finding that rapamycin can sensitize cancer cells to apoptosis, independent of 
mTOR  inhibition,  was  confirmed  by  our  laboratory  in  childhood  acute 
lymphoblastic leukemia (ALL) (Avellino R et al. 2005). This cancer comprises 
a heterogeneous variety of subtypes.  In most of these leukemias,  blasts  are 
sensitive to the apoptosis-inducing effect of rapamycin because of constitutive 
activation of the PI3k/Akt pathway, which sustains blast survival (Watowich 
SS et al. 1996). Rapamycin increased doxorubicin-induced cell death, even in 
samples that did not respond to PI3k inhibition, while wortmannin was unable 
to cooperate with the anthracycline drug. The apoptosis sensitizing effect of 
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rapamycin was counteracted by hyperexpression of the NF-B RelA subunit in 
leukemic cells (Avellino R et al. 2005). Increased cytotoxicity to doxorubicin 
was observed in leukemic cells depleted of FKBP51 (Romano MF et al. 2004). 
These  results  support  the  conclusion  that  rapamycin  may  also  be  effective 
against neoplasias that express the tumor suppressor PTEN.  Consistent with 
this conclusion, we found rapamycin retained the capacity to cooperate with 
NF-B-inducing chemotherapeutics  in  PTEN reconstituted  tumors  (Romano 
MF et al. 2004).
Melanoma
Melanocytes exert a protective role against UV radiation for the skin, by 
distributing pigment from melanosomes to keratinocytes. Cutaneous melanoma 
arises  from  uncontrolled  proliferation  of  melanocytes,  melanin-producing 
cells, located in the basal layer of the epidermis (Chin L. 2003). Melanoma can 
also occur in the eye (ocular), meninges and digestive tract and is the most 
aggressive  form of  skin  cancer,  surpassing  most  solid  tumors  in  terms  of 
metastatic  potential.  The  incidence  of  this  tumor  is  increasing.  Melanoma 
pathogenesis  is  driven  by  both  genetic  and  environmental  risk  factors.  Its 
incidence  is  influenced  by  skin  pigmentation,  sun-exposure  history  and 
geographical location. Melanoma progression can begin with the development 
of either dysplastic or benign nevi (common acquired or congenital) (Chin L. 
2003). These can then progress to the radial growth phase, in which the growth 
expands laterally, but remains localized to the epidermis. At this phase, cells 
are still  dependent on growth factors, and are not anchorage independent or 
tumorigenic.  Progression  to  the  vertical  growth  phase  is  hallmarked  by 
invasion  into  the  dermis,  subcutaneous  tissue  and  upper  epidermis.  In  the 
vertical  growth  phase,  cells  are  no  longer  growth  factor  dependent,  are 
anchorage independent and presage distal metastasis (Fig.4).
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Fig.4. Schematic representation of melanoma progression stages. Melanocytes 
are pigment-synthesizing cells that are normally confined to the basal layer of the epidermis.  
These cells, by  sending out arborizing dendritic processes, contact keratinocytes in basal and 
superficial  layers  of  the  skin,  thus  forming  an  epidermal  melanin  unit.  Once  within  the  
keratinocytes,  the  pigment  protects  the  skin  by  absorbing  and  scattering  harmful  solar 
radiation. Five distinct stages have been proposed in the evolution of melanoma on the basis of 
its  histological  location  and  stage  of  progression:  common  acquired  and  congenital  nevi 
without  dysplastic  changes;  dysplastic  nevi  with structural  and  architectural  atypia;  radial-
growth  phase  (RGP)  melanoma;  vertical-growth  phase  (VGP)  melanoma;  and  metastatic 
melanoma. Both benign and dysplastic nevi are characterized by disruption of the epidermal 
melanin unit, leading to increased numbers of melanocytes in relation to keratinocytes. These 
precursor  lesions  progress  to  in  situ  melanoma,  which  grow  laterally  and  remain  largely 
confined to the epidermis, so this stage is defined as the RGP melanoma. This is in contrast to  
the VGPmelanoma,  which both invades the upper layer  of the epidermis and beyond,  and 
penetrates  into  the  underlying  dermis  and  subcutaneous  tissue  through  the  basement 
membrane, forming expansile nodules of malignant cells. The transition from RGP toVGP is 
the  crucial  step  in  the  evolution  of  melanoma  that  presages  the  acquisition  of  metastatic 
potential  and  poor  clinical  outcome.  Consistent  with  that,  the  total  thickness/height  of  a 
primary melanoma lesion is still one of the most predictive parameters for metastatic disease 
and adverse clinical outcome (Chin L. 2003).
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Clinical  staging  of  melanoma  progresses  from  an  in  situ growth  to  one 
increasing in thickness and vertical invasion, to regional lymph-node spread 
and, finally, to distal metastasis. Vertical invasion may be representative of the 
degree  of  progression  and  is  often  measured  by  the  Breslow  thickness,  a 
measure of the thickness of the tumor from the upper layer of the epidermis to 
the innermost depth of invasion (Balch CM et al. 2001). The prognosis is bad 
in  advanced  stages  of  melanoma  because  of  resistance  to  conventional 
anticancer  treatments  and  the  high  metastatic  potential  of  this  tumor. 
Moreover, melanoma can remain quiescent for years after resection of primary 
tumor  and  then  recur;  recurrences  are  due  both  to  local  persistence  of 
malignant cells, after surgical resection, and to micro metastases derived from 
lymphatic  or  hematogenous  dissemination  (Norris  LB and Beam S.  2008). 
Currently,  no  efficient  therapeutic  strategies  are  available  to  control  the 
advanced disease. 
The  use  of  radiotherapy,  the  most  common  antitumor  treatment,  is 
controversial for advanced melanoma; it serves mainly as a palliative treatment 
because  of  the tumor’s  radioresistance.  The  response  to  ionizing  radiation 
involves  DNA  damage  recognition,  repair,  and  the  induction  of  signaling 
cascades  leading  to  cell  cycle  checkpoint  activation  and  stress-related 
responses. (Dewey WC et al. 1995; Wallace SS. 1994). Apoptosis is a common 
biological mechanism for eliminating damaged cells involving the activation 
of  enzymes  known  as  caspases,  and  leading  to  endonuclease-mediated 
internucleosomal fragmentation of DNA (Hengartner MO. 2000) (Fig.5). 
Fig.5. Apoptosis. Apoptosis is a common biological mechanism for eliminating damaged 
cells involving the activation of enzymes known as caspases,  and leading to endonuclease-
mediated internucleosomal fragmentation of DNA.
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Stress-inducing agents are able to activate also autophagy, namely type II cell 
death (Elliott A and Reiners Jr JJ. 2008; Ogata M et al. 2006). Autophagy is a 
process of intracellular  bulk degradation  in which cytoplasmic  components, 
including  organelles,  are  sequestered  within  double-membrane  vesicles  that 
deliver the contents to the lysosome/vacuole for degradation (Eskelinen EL. 
2008) (Fig.6).
Fig.6.  Autophagy. Autophagy  is  a  process  of  intracellular  bulk  degradation  in  which 
cytoplasmic  components,  including  organelles,  are  sequestered  within  double-membrane 
vesicles that deliver the contents to the lysosome/vacuole for degradation.
It  is controversial  whether this recently discovered process causes death or, 
instead,  protects  cells  (Baehrecke  EH.  2005).  Indeed,  the  products  derived 
from autophagy are recycled to maintain essential cellular processes. However, 
there  are  several  lines  of  evidence  that  support  a  role  for  autophagy  in 
increasing the threshold for apoptosis, thereby sustaining cell survival under 
conditions of stress (Mathew R et al. 2007). 
Activated NF-B is one of the pathways responsible for the radioresistance of 
melanoma  cells  and strategies  for  inhibiting  its  influence  are  proven to  be 
useful in restoring the radio-response of melanomas (Munshi A et al. 2004). 
FKBP51 involvment in control of NF-B activation supports a role for this 
protein in promoting radio-resistance.
18
AIM OF THE STUDY
Aim of this study was to investigate the role of FKBP51 in the control of 
response to ionizing radiation (IR) of malignant melanoma. In this regard, the 
present study was focussed on characterization of the role of FKBP51 in IR-
activation of NF-B signaling, and cell death pathways termed apoptosis, or 
programmed cell death type 1 and autophagy, or programmed cell death type 
2.  A  further  purpose  was  to  investigate  expression,  in  primary  melanoma 
samples, of FKBP51, whose expression is highly increased in melanoma cell 
lines, to find out eventual association with prognostic factors. Finally, study of 
FKBP51 expression was extended to a variety of human tumors, to find out 
eventual  protein  deregulation.  Results  from this  study  identify  a  candidate 
target  for  radio-sensitizing  strategies  against  malignant  melanoma  and  a 
potential novel tumoral biomarker.
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MATERIALS AND METHODS
Cell culture
The melanoma cell line SAN (Romano MF et al. 2004; Benassi B et al. 
2007) was established from a patient’s tumor lymphonodal metastasis and was 
provided by Dr.  Gabriella  Zupi  (Experimental  Preclinic  Laboratory,  Regina 
Elena Institute for Cancer Research, Roma, Italy). Cells were cultured in RPMI 
1640 medium (Lonza, Belgium) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), 200mM glutamine, and 100 U/ml penicillin-streptomycin 
(Lonza) at 37°C in a 5% CO2 humidified atmosphere. The melanoma cell lines 
G361 and SK-MEL-3 (Trotta PP et al. 1987) (derived from a primary tumor 
and  a  lymphonodal  metastasis,  respectively)  were  cultured  in  McCoy’s 
modified medium (Sigma Aldrich, Saint Louis, MO, USA) supplemented with 
10%  heat-inactivated  FBS,  200mM  glutamine  and  100  U/ml  penicillin-
streptomycin at 37°C in a 5% CO2 humidified atmosphere. The melanoma cell 
line A375 (Giard DJ et al. 1973) derived from a metastatic tumor, was cultured 
in  Dulbecco’s  Modified  Eagle’s  Medium (Lonza)  supplemented  with  15% 
heat-inactivated FBS, 200mM glutamine, and 100 U/ml penicillinstreptomycin 
at 37°C in a 5% CO2 humidified atmosphere.  G361, SK-MEL-3, and A375 
were kindly provided by Dr. Rosella Di Noto (CEINGE, Naples, Italy).
Cell transfection
 At 24 h before transfection,  cells  were seeded into six-well  plates at  a 
concentration of 2x105 cells/ml to obtain 30-60% confluence at  the time of 
transfection.  Then,  the cells  were transfected  with specific  short  interfering 
oligoribonucleotide (siRNA) or with a non-silencing oligoribonucleotide (NS 
RNA)  as  control,  at  a  final  concentration  of  50  nM  using  Metafectene 
(Biontex,  Munich,  Germany)  according  to  the  manufacturer’s 
recommendations.  NS  RNAs  and  siRNAs  corresponding  to  human  cDNA 
sequences  for  FKBP51, FKBP12,  RelA,  xIAP,  and Becn-1 were purchased 
from Qiagen (Germantown, Philadelphia, PA, USA) (Romano S et al. 2010). 
For over-expressing Becn-1, cells were transfected with a pEGFP-N1 vector 
carrying Becn-1 (kind gift of Dr. Sharon Tooze, London Research Institute, 
Lincoln's Inn Fields Laboratories, London, UK),  and with a pEGFP-N1 vector 
as control. At 48 h after transfection, cells were irradiated with a 6 MV X-ray 
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of  a  linear  accelerator  (Primus,  Siemens,  München,  Deutschland)  and 
processed according to the different experimental procedures.
Clonogenic assay
This assay was performed as described earlier (Franken NAP et al. 2006) 
Briefly, melanoma cells, not transfected and transfected with FKBP51 siRNA 
or with NS RNA, were irradiated at IR doses between 1 and 8 Gy, harvested 
and plated in triplicate at a density of 500 cells/plate. After 10 days, the formed 
colonies were stained with crystal violet and counted. The mean colony count 
was calculated for each treatment (both IR dose and type of cell transfection). 
The number of colonies in the irradiated dishes was divided by the number of 
colonies in the non-irradiated dishes and expressed as a percentage. The graph 
of  percent  survival  (y  axis)  against  IR  dose  (x  axis)  was  performed  in 
semilogarithmic scale.
Cell lysates, western blot and immunoprecipitation assay
Whole cell  lysates  were prepared by homogenization  in modified RIPA 
buffer. For phospho-IB, IB and IB detection, cytosolic extracts were 
obtained from cells resuspended in a different lysing buffer (Romano S et al. 
2010). Cell debris was removed by centrifugation. Protein concentration was 
determined using the Bradford protein assay. Cell lysates were equalized for 
total  protein,  run  in  10–14%  SDS  in  polyacrylamide  gel  electrophoresis 
(PAGE) and transferred onto a methanol-activated polyvinylidene difluoride 
membrane (Millipore, Tokyo, Japan), which was incubated with the primary 
antibody. The goat polyclonal antibodies against FKBP51, FKBP12, and Actin 
(Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA);  the  rabbit  polyclonal 
antibodies against  Becn-1, phospho-IB (Ser 32) IB,  IB (Santa Cruz 
Biotechnology),  LC3  (Novus  Biologicals,  Littleton,  CO,  USA),  caspase-7 
(Sigma,  Saint  Louis,  MO,  USA),  and  cleaved  caspase-3  (Cell  Signaling, 
Danvers,  MA,  USA)  were  used  diluted  1:500.  The  mouse  monoclonal 
antibodies  against  caspase-3  (specific  for  both  pro-caspase  and  cleaved 
caspase-3) (Sigma Aldrich), xIAP (Stressgene, San Diego, CA, USA) and Bax 
(Santa  Cruz  Biotechnology)  were  used  diluted  1:1000.  The  blots  were 
developed with an electrochemiluminescence system (ECL) (GE Healthcare-
Amersham,  Buckinghamshire,  UK).  For  immunoprecipitation  assay,  whole 
cell  lysates  were  prepared  by  melanoma  cells  not  irradiated  and  3h  after 
irradiation  with  4  Gy.  After  obtaining  a  homogeneous  suspension,  protein 
concentration  was  determined  using  the  Bradford  method  and  500  µg  of 
protein extract were precleared for 1 h. For immunoprecipitation, 15 µg anti-
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FKBP51 (rabbit polyclonal, H100) or anti-IKK/ (rabbit polyclonal, N-19) 
(Santa  Cruz  Biotechnology,  CA, USA) were  added together  with  25  µl  of 
protein  A/G-Sepharose  (Santa  Cruz  Biotechnology)  and  precipitation  took 
place  overnight  with  rotation  at  4°C.  Immunoprecipitated  and  whole  cell 
lysates were then separated by 14% SDS-PAGE and subjected to immuno-blot 
with goat polyclonal anti-FKBP51 (F-13), or the rabbit anti-IKK/.
Transmission electron microscopy
Melanoma cells, not transfected or transfected with Becn-1 siRNA, or with 
NS RNA, were irradiated at 4Gy, harvested after 6 h from IR and plated on 60 
mm  dishes.  At  30-50%  confluence,  the  cells  were  fixed  with  2% 
glutaraldehyde in 0.2M Hepes, pH 7.4, at room temperature for 30 min. The 
cells were scraped and pelleted, and the fixation was continued for 2 h. The 
cells  were  then  dehydrated  in  ethanol  and  embedded  in  epoxy resin.  Thin 
sections  were  cut  and  stained  with  uranyl  acetate  and  lead  citrate,  and 
examined  under  a  Jeol  JEM1200  EX2  Transmission  Electron  Microscope 
(Jeol, Tokyo, Japan). 
Nuclear exstracts, EMSA and oligonucleotides
Cell  nuclear  extracts  were  prepared following the  procedure thoroughly 
described (Romano S et  al.,  2010).  Protein  concentrations  were determined 
using the Bradford method. The NF-B oligonucleotide (Wallace SS. 1994) 
was end-labeled with [32P] ATP using a polynucleotide kinase (Roche, Basel, 
Switzerland). End labeled DNA fragments were incubated at room temperature 
for  20 min  with 5  g of  nuclear  protein,  in  the presence  of  an incubation 
mixture  (Romano  S,  2010).  In  supershifting  experiments,  rabbit  antibodies 
against  p105/p50, p65, cRel,  RelB (Santa Cruz Biotechnology),  and against 
p52  (kindly  provided  by  Professor  Shao-Cong  Sun,  Department  of 
Microbiology  and  Immunology,  Pennsylvania  State  University  College  of 
Medicine,  Hershey,  PA,  USA)  were  added  to  the  incubation  mixture.  In 
competition assays, a 50x molar excess of NF-B, or NFAT cold oligo, was 
added to the incubation mixture. Protein-DNA complexes were separated from 
the free probe on a 6% polyacrylamide  (w/v)  gel  run in 0.25x Tris  Borate 
EDTA buffer at 200 mV for 3 h at room temperature. The gels were dried and 
exposed to X-ray film (Fuji film, L.E.P., Naples, Italy).
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Analysis of apoptosis
Caspase-3 and -9 activity  was determined using the Carboxyfluorescein 
Fluorochrome  Inhibitor  of  Caspases  Assay  (FLICA)  Kits  (B-Bridge 
International,  San  Jose,  USA,)  according  to  the  instructions  of  the 
manufacturer.  Cells  are  permeable  to  the  fluorochrome  inhibitor  that  binds 
covalently to the activated caspase, thereby inhibiting enzymatic activity. Cells 
were analyzed by flow cytometry and the green fluorescent signal was a direct 
measure  of  the  number  of  active  caspases  (Romano  S  et  al.  2010). 
Phosphatidylserine  externalization,  investigated  by  annexin  V  staining,  and 
analysis of DNA content by propidium iodide incorporation were performed 
by  flow  cytometry.  The  peptide  caspase-3  inhibitor  Z-Asp-Glu-Val-Asp 
fluoromethyl ketone (Z-DEVD-fmk) was purchased by Sigma Aldrich. 
Real-time PCR
Total  RNA  was  isolated  by  Trizol  (Invitrogen,  Carlsbad,  CA,  USA)  from 
melanoma cells harvested 6 h after IR, and from peripheral blood lymphocytes 
(PBLs), according to the instructions of the manufacturer. From paraffinized 
tumors  RNA  was  isolated  using  the  High  Pure  RNA  Paraffin  Kit  (Roche 
Diagnostics  GmbH,  Mannheim,  Germany)  according  to  the  manufacturer’s 
instructions. In all samples, a total of 1 g of each RNA was used for cDNA 
synthesis  with  Moloney  Murine  Leukemia  Virus  Reverse  Transcriptase 
(Invitrogen).  Gene  expression  was  quantified  by  real-time  PCR  using  the 
iQSYBR Green Supermix (Biorad, Hercules, CA, USA) and specific real-time-
validated QuantiTect primers for Bax, Becn-1, and XIAP (Qiagen) and specific 
primers  for  -actin  (Fw 
5’CGACAGGATGCAGAAGGAGA3’;Rev5’CGTCATACTCCTGCTTGCTT
GCTG3’)  and FKBP51 (Fw 5’GTGGGGAATGGTGAGGAAACGC3’;  Rev 
5’CATGGTAGCCACCCCAATGTCC3’).  Relative  quantitation  of  each 
transcript across multiple samples was performed by using a coamplified  -
actin internal control for sample normalization. For paraffinized tumors RNA 
the  values  of  each  sample  were  compared  to  PBL  (expression=1)  for  an 
estimate of the relative expression change fold of FKBP51. 
Confocal microscopy
Cells  were  fixed,  permeabilized  and  incubated  with  mouse  monoclonal 
anti-Bax  (Santa  Cruz  Biotechnology)  and  rabbit  polyclonal  LC3  (Novus 
Biologicals),  diluted  1:40  in  PBS  0.5%  BSA  for  1  h  in  a  humidified 
atmosphere. The cells were then extensively washed in PBS before staining 
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with secondary goat anti-mouse Alexa Fluor 546 and anti-rabbit Alexa Fluor 
488 (Molecular Probe, Invitrogen Corporation,  Carlsbad, CA, USA). Nuclei 
were counterstained with Hoechst 33258 and the cells were mounted on glass 
slides with PBS containing 50% glycerol. The analysis of immunofluorescence 
was performed with a confocal laser scanner microscopy Zeiss 510 LSM (Carl 
Zeiss Microimaging GmbH, München, Germany), equipped with Argon ionic 
laser (Carl Zeiss Microimaging GmbH, München, Germany) (Romano S et al. 
2010). Images for the double-staining immunofluorescence were acquired by 
sequential scanning to eliminate the cross talk of chromophores in the green 
and  red  channels  and  then  saved  in  TIFF  format  to  prevent  the  loss  of 
information.  They had been acquired  with a resolution of 1024x1024 pixel 
with the confocal pinhole set to one Airey unit. 
Cell sorting and immunostaining of ABCG2+cells
SAN melanoma cells were incubated with a monoclonal antibody against 
human  ABCG2-pycoerythrin  (PE)  conjugated  (R&D Systems,  Minneapolis, 
MN, USA). Briefly, cells were fixed, and intracellular indirect immunostaining 
was performed with anti-FKBP51 (H-100) (Santa Cruz Biotechnology) and a 
secondary fluorescein isothiocyanate (FITC)-conjugated antibody. Expression 
of  FKBP51  in  both  ABCG2+ and  ABCG2- cells  was  analyzed  in  flow 
cytometry  by  using  the  ABCG2-PE/SSc  gating  strategy.  For  the 
immunohistochemistry of ABCG2+ cells,  these were sorted  from the whole 
cells of the melanoma cell line SAN with a BD FACSAria (BD Biosciences). 
The ABCG2+ population was >77% in purified cells.  The sorted cells  were 
immediately fixed, deposited on a slide (Cytoslide Shandon, Waltham, MA, 
USA) by spinning in a cytocentrifuge (Cytospin 3, Shandon) and subjected to 
FKBP51 immunohistochemical staining.
Immuhistochemistry
Serial sections of 4-mm thickness from routinely formalin-fixed, paraffin-
embedded blocks were cut for each case of cutaneous malignant melanoma 
(CMM), breast, lung, prostate, ovary, pancreas and colon cancer and relative 
normal  tisuues.  Section  were  then  mounted  on  poly-l-lysine-coated  glass 
slides,  as  described  earlier  (Giard  DJ  et  al.  1973).  Briefly,  deparaffinized 
sections were incubated with the anti-FKBP51 primary antibody (F-13; Santa 
Cruz Biotechnology) diluted 1:50 overnight at 4°C. The standard streptavidin-
biotin-peroxidase complex technique was performed. Hematoxylin was used 
for  nuclear  counterstaining.  Only cells  with a  definite  brown cytoplasmatic 
immunostaining  were  judged  as  positive  for  FKBP51  antibody.  The 
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immunohistochemical  expression  of  FKBP51  in  CMM  was  evaluated 
semiquantitatively as the percentage of positive tumor cells among the total 
melanoma  cells  present  in  at  least  10  representative  fields  and  scored 
according  to  an  arbitrary  scale  (Staibano  et  al.  2005)  as  follows:  0  (no 
immunopositive cells); + (<5% of positive cells); ++ (5<25% of positive cells); 
+++ (>25% of positive cells).
Animal studies
SAN melanoma cells, 3x106 in a volume of 100 l PBS, were injected s.c. 
into one flank of 24 6-week-old athymic nu/nu mice (Charles RiverLaboratory, 
Wilmington, MA, USA). Mice were maintained under specific pathogen free 
conditions in the Laboratory Animal Facility of the National Cancer Institute, 
G Pascale Foundation, Naples, Italy. All studies were conducted in accordance 
with Italian regulations for experimentations on animals. Mice were observed 
daily  for  the  visual  appearance  of  tumors  at  the  injection  sites.  Tumor 
diameters  were  measured  using  calipers  and  calculated  as  the  mean  value 
between the shortest and the longest diameters. When tumors reached ~10mm 
in  mean  diameter,  mice  were  subjected  to  a  single  intratumor  injection  of 
FKBP51 siRNA, or NS RNA, subjected to tumor irradiation and killed 24 or 
48 h after irradiation (Romano S et al. 2010). Each tumor was divided into two 
parts:  one  portion  was  formalin-fixed  and  paraffinembedded  for 
immunohistochemistry  and  the  other  was  processed  for  the  preparation  of 
whole  cell  lysates.  For  immunohistochemical  assays,  5-mm-thick  paraffin-
embedded sections were incubated with a rabbit polyclonal antibody against 
cleaved  caspase-3  (Asp175)  (Cell  Signaling)  or  isotype-matched  control 
antibody.  Lysates  of  excised  tumors  were  prepared  by  homogenization  in 
modified  RIPA buffer  in  a  Dounce Homogenizer  (Romano  S et  al.  2010). 
Samples  were  equalized  for  total  protein  and  run  in  SDS-PAGE 
electrophoresis.  Western blot filter was incubated with the rabbit polyclonal 
antibody for cleaved caspase-3 (Asp175) (Cell Signaling).
Statistical analysis
The results reported are the mean and standard deviation of independent 
experiments.  The  statistical  significance  of  differences  between  means  was 
estimated using Student’s t-test. The 2-test was used to assess the difference 
between  categorical  variables.  The  Spearman’s  rank  correlation  coefficient 
was  used  for  non-parametric  data.  Values  of  P0.05  were  considered 
statistically significant. The statistical analysis was performed using the SPSS 
statistical package (SPSS Inc., Chicago, IL, USA).
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RESULTS
FKBP51  downmodulation  sensitizes  melanoma  cells  to  IR-
induced apoptosis 
In  order  to  investigate  the  role  of  FKBP51  in  the  cellular  response  to 
ionizing  radiations  (IR),  melanoma  cells  were  transfected  with  a  short 
interfering (si) RNA. Such siRNA was previously (Romano MF. 2004) shown 
to efficiently downmodulate the protein and to be specific for FKBP51, since 
other FKBP expression levels were not affected (Romano S et al. 2008). In 
Figure 7, representative results of the effect of FKBP51 gene silencing in the 
SAN melanoma cell line are shown. The specificity of the downmodulating 
effect of FKBP51 siRNA was also shown (Fig.7A). A clonogenic assay was 
performed using cells  transfected  with FKBP51 siRNA, non-silencing (NS) 
RNA,  or  nothing.  Melanoma  cells,  knocked  down for  FKBP51,  showed  a 
sensitizing enhancement ratio (Chen AY et al. 1997) of 1.5 (7.2 Gy/4.8 Gy). 
This ratio was calculated on the basis of the radiation dose necessary to obtain 
the end point of a 90% inhibition of colony formation. As shown in figure 7B, 
the line corresponding to 10% survival intercepts the dose response curve of 
control cells (not transfected or transfected with NS RNA) at 7.2 Gy, whereas 
that of FKBP51-depleted cells  occurred at 4.8 Gy.  This result  suggests that 
decreased  levels  of  FKBP51  remarkably  increase  the  cytotoxic  effect  of 
radiation in melanoma cells. To investigate the cellular response to Rx in cells 
depleted of FKBP51, we investigated by western blot hallmarks of autophagy 
(Kabeya Y et al. 2000) and apoptosis (Hengartner MO. 2000), in particular the 
autophagic  protein  Beclin-1  (Becn-1),  the  light  chain  3  (LC3)-I  to  LC3-II 
conversion, the pro-apoptotic protein Bax and the active fragments of caspase 
3  and 7.  Whole  cell  lysates  were  prepared  from cells  transfected  with  the 
specific siRNA or NS RNA. At 48 h after transfection, cells were exposed to 
4Gy dose of IR and harvested at 0, 2, 4, 6, and 9 h. Figure 7C shows the 
presence of the autophagosome membrane recruited LC3-II isoform in non-
irradiated  cells,  both  transfected  and not  transfected  with  FKBP51 siRNA, 
which is consistent with a basal level of autophagy. The isoform disappeared 6 
h after IR exposure in FKBP51-depleted cells, but not in NS RNA-transfected 
cells. An increase in Becn-1 levels was detected in non-silenced cells after 4 h, 
suggesting  that  this  increase  had  a  role  in  sustaining  the  LC3-I  to  LC3-II 
conversion. In contrast, the appearance of the active fragment of the execution 
caspases-3 and -7 (Chandler JM et al. 1998) in FKBP51-depleted cells, as early 
as 4 h after IR exposure, suggests the activation of apoptosis. Interestingly, 
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Bax levels decreased in irradiated non-silenced cells, concomitant to increase 
of Becn-1 levels and LC3-I to LC3-II conversion. 
Fig.7.  Activation  of  apoptosis  in  irradiated  melanoma  cells  depleted  of  
FKBP51.  (A) Western blot assay of FKBP51 in cell lysates obtained from the melanoma 
cell  line SAN transfected  with FKBP51 siRNA, FKBP12 siRNA, or  a  non-silencing (NS) 
oligoribonucleotide  as  control.  (B)  Clonogenic  assay  of  irradiated  cells  transfected  with 
FKBP51 siRNA, NS RNA, or not transfected. Cells were irradiated with the indicated doses of 
ionizing radiation (Rx), harvested, and plated in triplicate. After 10 days,  the colonies were 
stained  with  crystal  violet  and  counted.  (C)  Western  blot  assay  of  Becn-1,  LC3-II,  Bax, 
caspase-3  and  -7  in  cell  lysates  prepared  from melanoma  cells  transfected  with  FKBP51 
siRNA or NS RNA. Cells were irradiated with 4 Gy IR and harvested at the indicated times.
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Autophagy was confirmed by transmission electron microscopy; a quantitation 
analysis  of  autophagic  profiles/cell  area  showed  a  clear  increase  in 
autophagosomes 6 h after IR exposure (Fig.8A). 
Apoptosis  was  confirmed  by  flow  cytometry.  Figure  8B  shows  the  flow 
cytometric histograms of caspase-9 and -3 activation, annexin V binding, and 
propidium iodide incorporation in irradiated cells. A measure of cell death by 
annexin  V  binding  in  15  independent  experiments  clearly  showed  that  IR 
induced  a  remarkable  increase  in  the  cell  death  of  FKBP51-depleted  cells 
(48.7±11.8)  compared with that  of  non-silenced cells  (26.7±8.1) (P=0.000). 
The mean values of cell death for non-irradiated, non-silenced or silenced cells 
were 18.0±4.4 and 27.9±8.5, respectively (P=0.022). This finding suggests that 
knocking down of FKBP51 reduces the threshold for cell death. The induction 
of apoptosis in FKBP51-depleted cells was confirmed using the pan-caspase 
inhibitor z-Valine-Alanine-Aspartic Acid (zVAD), which clearly inhibited IR-
induced cell death (Fig.8C). The sensitizing effect of FKBP51 siRNA on IR-
induced  apoptosis  was  observed  also  in  G361,  A375,  and  SK-MEL-3 
melanoma  cell  lines  (Figure  9).  These  data  showed  that  FKBP51  plays  a 
relevant role in counteracting apoptotic processes stimulated by IR. Cellular 
events consistent with autophagy, such as an increase in Becn-1 levels and the 
autophagosome membrane associated LC3-II isoform, but very few with cell 
death were observed in irradiated melanoma cells, suggesting that  autophagy 
supports  the  survival  of  the  tumor  cells. Transmission  electron  microscopy 
showed an  increased  number  of  autophagic  vacuoles  in  irradiated  cells.  In 
contrast, typical biochemical markers of apoptosis, such as cleaved caspase-9 
and  -3,  phosphatidylserine  externalization  on  the  plasma  membrane,  and 
hypodiploid  DNA  in  melanoma  cell  nuclei,  were  observed  in  irradiated 
melanoma cells pre-treated with FKBP51 siRNA. These data suggested that 
FKBP51 plays a relevant role in counteracting apoptotic processes stimulated 
by IR. In particular it promotes an autophagic response in irradiated melanoma 
cells,  which enhances the treshold for apoptosis and most probably sustains 
cell survival. 
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Fig.8.  IR induces  autophagy in  melanoma but  apoptosis  in  condition  of  
FKBP51  knockdown.  (A)  Transmission  electron  microscopy  image  of  an  irradiated 
melanoma cell, 6 h after exposure at a 4 Gy dose of ionizing radiation. Scale bar, 500 nm. 
Graphic representation of autophagic profiles/cell area in non-irradiated (0 h) and irradiated (6 
h) cells. AVd, degradative autophagic compartment; AVi, initial  autophagosome.  (B) Flow 
cytometric  histograms of  active  caspases-9 and -3,  annexin V binding,  and the propidium 
iodide incorporation of SAN melanoma cells transfected with NS RNA or FKBP51 siRNA. 
Cells were  irradiated  with 4 Gy  and harvested  after  6,  48, and 72 h to measure  caspase 
activity,  annexinV binding,  and  propidium iodide  incorporation,  respectively.  (C)  Graphic 
representation of the apoptosis of melanoma cells transfected with FKBP51 siRNA. At 48 h 
after transfection, cells were incubated with the indicated doses of zVAD and irradiated with 4 
Gy of IR. After another 48 h, cells were harvested and apoptosis was determined by annexin V 
staining.
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Fig.9.  FKBP51  knock-down  sensitizes  different  melanoma  cell  line  to  
apoptosis. Graphic representation of the apoptosis of SK-MEL3, G361 and A375 melanoma 
cell transfected with NS RNA or FKBP51 siRNA. Forty-eight hours after transfection, cells 
were irradiated at  4Gy of IR and harvested after  further 48 h. Apoptosis was analyzed by 
annexin V staining in flow cytometry; in figure are shown averages and standard deviations of 
five different experiments.
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FKBP51 is essential for IR-induced activation of NF-B 
IR induces NF-B activation (HabrakenY et al. 2006). The kinetics of IB 
degradation showed a decrease in IB levels and the complete disappearance 
of IB, as early as 4 h after irradiation, with a return to the basal level after 
20 h (Fig.10A). The activation of NF-B was confirmed by electrophoretic gel 
mobility shift assay (EMSA) (Fig.10B). FKBP51 is an important co-factor of 
IKK  kinase  complex  (Boumwester  T.  2004).  Figure  10C  shows  that  a 
molecular  interaction  between  FKBP51 and IKK occurs  during IR, in fact, 
IKK co-immunoprecipitated with FKBP51 in irradiated cells. The relevant role 
of  FKBP51  in  IKK  kinase  function  was  confirmed  by  measuring  IB 
degradation and  the levels of phospho-IB (Ser 32)  in irradiated FKBP51-
silenced  cells,  in  comparison  with  irradiated  non-silenced  cells.  Increased 
levels of phospho-IB could be detected in irradiated melanoma cells, but not 
when FKBP51 was downmodulated (Fig.10D). 
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Fig.10.  IR  induces  NF-B  activation  and  FKBP51/IKK  interaction.  (A) 
Western blot assay of IkB and IkB levels in cytoplasmic extracts prepared from irradiated 
SAN melanoma cells harvested at the indicated times. (B) An electrophoretic mobility shift 
assay (EMSA) using nuclear extracts prepared from irradiated melanoma cells harvested at the 
indicated times. The last two lanes show a competition assay performed with the same B cold 
oligonucleotide or an unrelated cold oligonucleotide (NFAT) that was added to the incubation 
mixture. (C) Total cell lysates were prepared by melanoma cells not irradiated and 3h after 
irradiation with 4 Gy. Cell lysates were immunoprecipitated (IP) with FKBP51 antibody, or 
IKK/ antibody.  Immunoprecipitated and total lysates were then subjected to western blot 
and FKBP51 and IKK/ were analyzed. (D) Western blot assay of IB and phospho- IB 
(Ser 32) levels in cytoplasmic extracts prepared from melanoma SAN cells transfected with 
FKBP51 siRNA, or a NS RNA as control. After 48h from transfection cells were irradiated at  
4Gy and harvested at the indicated times.
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In line with NF-B activation, an increase in the level of the caspase inhibitor 
X-linked  inhibitor  of  apoptosis  protein  (xIAP)  was  observed.  As  expected, 
such  an  increase  was  not  observed  in  FKBP51-silenced  cells  (Fig.  11A). 
Consistent  with  the  notion  that  xIAP transcription  is  under  NF-B control 
(Karin M et al.  2002),  reduced levels of XIAP mRNA, both basal  and IR-
induced, were found in p65-silenced cells compared with those in non-silenced 
cells  (Fig.11B).  The  upregulation  of  xIAP  had  a  role  in  the  inhibition  of 
irradiated  melanoma  cell  apoptosis.  In  fact,  when  xIAP  expression  was 
silenced with a specific siRNA, the IR stimulated caspase activation and cell 
death (Fig.11C). Taken together, these findings suggest that FKBP51-silenced 
cells fail to activate NF-B-controlled anti-apoptotic genes when irradiated. 
33
Fig.11. Lack of NF-B activation and xIAP induction in melanoma cells  
depleted of FKBP51. (A) EMSA using nuclear extracts and western blot assay of whole 
cell lysates obtained from melanoma cells transfected with NS RNA or FKBP51 siRNA. At 48 
h  after  transfection,  cells  were  irradiated  with  4  Gy  of  IR  and,  after  an  additional  6  h 
incubation, harvested for the preparation of both nuclear extracts and whole cell lysates. (B) 
Effect of xIAP downmodulation on IR-induced apoptosis. Western blot assay of xIAP levels in 
melanoma cells transfected with NS RNA or xIAP siRNA. At 48 h after transfection, cells 
were irradiated with 4 Gy IR. Cells were harvested after 6 h for whole cell lysate preparation.  
At the same time, a flow cytometric analysis of caspase-3 activation was performed. The graph 
represents the mean values and standard deviations of active caspase-3 from three different 
experiments, each performed in triplicate. Apoptosis was measured 48 h after irradiation by 
annexin V binding. A representative result of three independent experiments, performed in 
triplicate, is shown. (C) Normalized expression rates of XIAP mRNA (a.u.: arbitrary units) in 
melanoma cells SAN, which were transfected with p65 siRNA or a NS RNA, and irradiated or  
not with a 4 Gy dose. Vertical bars indicate standard deviations. Values were obtained from 
three independent experiments.
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Rx-induced NF-B sustains autophagy
In order to investigate whether the levels of Becn-1 were enhanced by NF-
B activation, we attempted to downmodulate the p65 subunit of NF-B. The 
supershift assay provided evidence that p65 represents the main component of 
the NF-B complex activated by IR in our cell system. As shown in figure 
12A, the IR-induced NF-B band was supershifted by anti-p50 and anti-p65 
antibodies.  Melanoma cells  transfected  with  p65 siRNA,  or  a  NS RNA as 
control,  were  irradiated  and,  after  6  h,  total  cell  lysates  were  prepared.  A 
western blot assay showed that p65 siRNA, but not NS RNA, downmodulated 
the protein (Fig.12B). Radiation treatment enhanced the levels of Becn-1 in 
non-silenced  cells,  but  this  was  not  observed  in  cells  depleted  of  p65.  An 
increase in the levels of the LC3-II isoform was found in irradiated cells, but 
not  when  p65  was  downmodulated  (Fig.12B).  The  IR-induced  increase  in 
Becn-1 protein  was  associated  to  increase  in  BECN-1 mRNA levels.  Such 
increase was not observed in p65-silenced cells (Fig.12C). This result suggests 
that p65 was essential for Becn-1 expression. Our finding is in accordance with 
the very recent demonstration that p65 exerts transcriptional control on BECN-
1 gene expression (Copetti T et al. 2009). 
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Fig.12. NF-B promotes cell  survival by enhancing the expression of the  
autophagic protein beclin-1.   (A) Supershift assay of a nuclear extract prepared from 
SAN melanoma cells 6 h after a 4 Gy dose of IR. The extract was incubated with [-32P] ATP 
end-labeled  NF-B consensus  oligonucleotide  in  the  absence  or  presence  of  the  indicated 
antibodies against NF-B and run in a 6% acrylamide gel electrophoresis. (B) Western blot 
assay of p65, Becn-1, and LC3-II levels in melanoma cells transfected with NS RNA or p65 
siRNA. At 48 h after transfection, cells were irradiated with 4 Gy Rx. Cells were harvested  
after 6 h for whole cell lysate preparation. (C) Normalized expression rates of BECN-1 mRNA 
(a.u., arbitrary units) in melanoma cells SAN, which were transfected with p65 siRNA or a NS 
RNA, and irradiated or not with a 4 Gy dose. Vertical bars indicate standard deviations. Values 
were obtained from three independent experiments. 
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To investigate  whether  Becn-1,  an  important  component  of  the  autophagic 
machinery (Eskelinen EL. 2008; Baehrecke EH. 2005; Mathew R et al. 2007), 
has  a  role  in  the  apoptosis  inhibition  of  irradiated  cells,  we  used  specific 
siRNA to downmodulate Becn-1. A western blot assay of whole cell extracts 
prepared from cells  6 h after irradiation showed an increase in the level of 
LC3-II isoform in cells transfected with NS RNA, but not those depleted of 
Becn-1  by  specific  siRNA  (Fig.13A).  This  finding  was  confirmed  by 
transmission  electron  microscopy;  we  performed  TEM  analysis  of  Becn-1 
silenced cells, at times 0 and 6 h after irradiation. In accordance with previous 
results,  there  was  no  induction  of  autophagy  after  irradiation  of  Becn-1 
silenced cells. A quantitation analysis of autophagic profiles/cell area showed a 
clear decrease in autophagosomes 6 h after IR exposure of Becn-1 silenced 
cells. Representative images of the cells are shown in figure 13B. These results 
are in accordance with the concept that Becn-1 is essential for the activation of 
autophagy (Eskelinen EL. 2008; Baehrecke EH. 2005; Mathew R et al. 2007). 
An analysis of cell death after an additional 40 h of incubation showed that the 
percentage  of annexin V-positive cells  clearly increased in Becn-1-depleted 
cells (Fig.13A).
Fig.13. Becn-1 exerts an essential role in apoptosis inhibition in melanoma  
cell.  (A) The effect of Becn-1 depletion on IR-induced apoptosis. A representative western 
blot of Becn-1 levels in melanoma cells transfected with NS RNA or Becn-1 siRNA is shown.  
At 48 h after transfection, cells were irradiated with 4 Gy IR. A portion of cells was harvested  
after 6 h for whole cell lysate preparation. After an additional 42 h, the remaining cells were  
harvested and apoptosis was measured by annexin V binding. A representative result of three 
independent  experiments,  each  performed  in  triplicate,  is  shown.  (B)  Representative  TEM 
images of Becn-1 silenced cells, at times 0 and 6h after irradiation with a 4Gy dose. Scale bar, 
500nm.
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In order to confirm these data, we analyzed apoptosis also in presence of high 
levels  of  Beclin-1.  Melanoma cells  were transfected with a  vector  carrying 
EGFP-tagged BECN-1 to over-express beclin-1, or an EGFP vector as control. 
Transfection efficiency was assessed by both a flow cytometric analysis and a 
western blot assay of Beclin-1 and LC3 (Fig.14A,B). We found that 35.5% and 
29.8%  of  cells,  transfected  with  EGFP  and  BECN-1/EGFP,  respectively, 
expressed  the  exogenous  gene.  Exogenous  beclin-1  was  functional,  as 
suggested by increased levels of LC3 II isoform in cells transfected with the 
fusion  protein,  compared  to  cells  transfected  with  control  vector,  which 
indicates an increase in basal autophagy. To investigate the effect of Becn-1 
over-expression  on  apoptosis  of  FKBP51  depleted  cells,  we  co-transfected 
BECLIN1/EGFP plasmid (or EGFP plasmid as control) and FKBP51 siRNA. 
Forty-eight h after irradiation, cells were collected, stained with annexin V-PE 
and analyzed by flow cytometry. Green fluorescent cells were gated as in A, 
according to FL-1/SSc parameters, and then the percentage of annexin V-PE 
positive cells was calculated.  Beclin-1 over-expression clearly decreased the 
levels  of apoptosis,  that  were lower than those of cells  co-transfected with 
EGFP and FKBP51 siRNA (Fig.14C). To confirm apoptosis, we measured the 
levels of active caspase-3 by indirect immunofluorescence. In accordance with 
apoptosis  data,  the  levels  of  active  caspase-3  were  reduced  in  cells  over-
expressing beclin1 (Fig.14D). These findings suggest that activation of NF-B 
in irradiated melanoma induces autophagy and that this mechanism is, at least 
in part, responsible for lack of cell death.
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Fig.14. Becn-1 overexpression inhibits apoptosis in melanoma cell.  (A) Flow 
cytometric  histograms  of  melanoma cells  transfected  with  a  vector  carrying  EGFP-tagged 
BECN-1 or an EGFP vector as control. A gate was placed on EGFP expressing cells based on 
FL1/SSc parameters. The percentages of EGFP+ cells were: 0.6, 35.5, 29.8 in not transfected, 
EGFP-transfected and BECN-1/ EGFP-transfected cells, respectively. (B) Western blot assay 
of Beclin1 and LC3 levels in cell lysates prepared from cells transfected with BECN-1/EGFP 
or EGFP. (C) Analysis of apoptosis of melanoma cells co-transfected with NS RNA+EGFP, 
NS  RNA+BECN-1/EGFP,  FKBP51  siRNA+EGFP  and  FKBP51  siRNA+  BECN-1/EGFP. 
Cells were irradiated after 48h from transfection and harvested after a further 48 h incubation. 
Apoptosis was analyzed by flow cytometry. The percentage of annexin V positive events was 
calculated in cells gated as in A. Mean values and standard deviations of three independent  
experiments, each performed in triplicate, are represented. (D) Flow cytometric histograms of 
cleaved  caspase-3.  Cells,  co-transfected  with  FKBP51  siRNA+EGFP   and  FKBP51 
siRNA+BECN-1/EGFP, were harvested after 0, 4 and 6h from irradiation at 4Gy. Then, cells  
were  fixed,  permeabilized,  and  incubated  with  a  cleaved  caspase-3  antibody.  Cells  were 
analyzed  by flow cytometry and the percentage  of cells  expressing cleaved caspase-3 was 
calculated in a gate performed as in A.
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Rx-induced autophagy increases the threshold for apoptosis
To  clarify  the  mechanism  by  which  Becn-1  inhibited  apoptosis,  we 
investigated  the  levels  of  Bax,  which  is  an  important  component  of  the 
permeability transition pore in mitochondrion-dependent apoptosis (Kim H et 
al.  2006).  Western blot  showed reduced Bax levels  in irradiated melanoma 
cells, which is consistent with its degradation. In Becn-1-silenced cells, Bax 
levels were higher compared with those in non-silenced cells after irradiation 
(Fig.15A).  Normalized  expression rates of  Bax mRNA in cells  transfected 
with BECN-1 siRNA, or a NS RNA, by Real-time PCR, did not show any 
relevant increase of Bax transcript after depletion of Becn-1, thus suggesting a 
post-transcrptional regulation (Fig.15B).
Fig.15.  Becn-1 downregulation  counteracts  bax degradation in irradiated  
melanoma  cell.  (A)  The  effect  of  IR  on  Bax  levels  in  Becn-1-depleted  cells.  A 
representative western blot of Bax levels in melanoma cells transfected with NS RNA or Becn-
1 siRNA is shown. At 48 h after transfection, cells were irradiated with 4 Gy IR. Cells were  
harvested after 4 h for whole cell lysate preparation. (B) Normalized expression rates of  Bax 
mRNA in cells transfected with BECN-1 siRNA or a NS RNA, by Real-time PCR.
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Bax  localization  was  investigated  by  confocal  microscopy,  in  double 
fluorescence with LC3 (Fig.16A). Bax was mostly localized in the nucleus, in 
basal conditions, and to some extent in the cytosol. After irradiation, nuclear 
Bax  apparently  translocated  to  the  cytosol.  The  presence  of  colocalization 
areas in LC3 aggregates (see enlarged detail in Fig.16A) suggests a possible 
inclusion  of  Bax  in  autophagic  vacuoles  (Fig.16A).  A  semi-quantitative 
western  blot  analysis  of  Bax  levels  in  cells  irradiated,  in  the  absence  or 
presence  of  inhibitors  of  lysosomal  proteolysis,  showed  a  decrease  in  Bax 
levels in irradiated cells, but not when inhibitors of lysosomal proteases were 
added  to  the  cell  culture  (Fig.16B).  These  findings  confirm  that  Becn-1 
expression  is  controlled  by  NF-B.  Moreover,  by  showing  the  IR-induced 
autophagic degradation of Bax, these results provide an explanation through 
which autophagy represses apoptosis.
Fig.16. IR induces Bax delocalization and degradation. (A) Confocal images of 
cells fixed after 0, 4 h, and 6 h from irradiation with 4 Gy and stained with anti-Bax (red  
fluorescence) and anti-LC3 (green fluorescence). Enlarged detail of colocalization areas. Bar 5 
mm. (B) Western blot of Bax levels in melanoma cells irradiated for 6 h with 4 Gy, in the  
absence or presence of 0.25mM leupeptin and 10  g/ml pepstatin. Protease inhibitors were 
added to the culture medium 1 h before cell harvest. Bax expression levels were quantified by 
densitometry using NIH Image 1.61 for Macintosh. Integrated optical densities, normalized to 
actin, were expressed versus baseline level.
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FKBP51  is  expressed  in  malignant  melanoma-stem/initiating  
cells
Normal  stem  cells  have  a  high  drug  efflux  capability  because  of  the 
expression levels of ATP-binding cassette (ABC) transporters, which actively 
pump drugs out of the cell. The ABC, subfamily G, member 2 (ABCG2) is a 
member of this superfamily of ABC transporter proteins, and it is known to be 
not  only  a  member  of  the  membrane  transporters  implicated  in  multidrug 
resistance but also a molecular determinant of cancer stem/initiating cells of 
melanoma (Monzani E et al. 2007). To find out whether FKBP51 targeting can 
overcome radioresistance in such cells  with enhanced tumorigenic potential, 
we investigated if they expressed this immunophilin. The FKBP51 expression 
was  determined  by  flow  cytometry  and  immunohistochemistry.  After  the 
acquisition  of  1x106 cells  with  a  flow  cytometer,  a  gate  was  placed  for 
ABCG2+ cells (0.5% of total cells), according to ABCG2-PE/SSc parameters 
(Fig.17A). The expression of FKBP51 in gated cells was then analyzed in the 
FL-1 channel. The percentage of FKBP51+ events was comparable in ABCG2+ 
and ABCG2- cells, whereas the mean fluorescence intensity (MFI) was clearly 
higher in ABCG2+ cells, when compared with that in ABCG2- cells, suggesting 
an  increased  production  of  FKBP51  in  cells  with  enhanced  tumorigenic 
potential.  The  expression  of  FKBP51  in  ABCG2+ cells  was  confirmed  by 
immunohistochemistry  of  cells  sorted  with  the  BD  FACSAria  cell  sorting 
system (BD Biosciences, San Jose, CA USA) (Fig.17B). We then investigated 
the  effect  of  IR  on  the  apoptosis  of  ABCG2+ cells.  Forty-eight  h  after 
irradiation, melanoma cells transfected with NS RNA or FKBP51 RNA were 
harvested and stained with ABCG2-PE and annexin V-FITC. The enhanced 
percentage  of  annexin  V-positive  events  in  ABCG2  gated  cells  clearly 
indicated  a  radiosensitizing  effect  of  FKBP51  siRNA  on  these  cells.  This 
biparametric analysis of apoptosis was performed also in other melanoma cell 
lines called SK-MEL3, G361 and A375. In conclusion, we demonstrated that 
ABCG2+  melanoma cells  contain  intracytoplasmic  FKBP51 at  higher  levels 
than ABCG2-  cells. Moreover, ABCG2+ cells are also killed by IR after pre-
treatment  with siRNA. Taken together,  these findings suggest that FKBP51 
may be a suitable target for eliminating cancer-stem cells of melanoma.
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Fig.17. FKBP51 is expressed in ABCG2+ cells. (A) Flow cytometric histograms of 
the  ABCG2 gating  strategy  and  FKBP51  expression  in  SAN melanoma cells.  Cells  were 
stained with PE-conjugated isotype control antibody or mouse monoclonal ABCG2-PE. The 
cells were then fixed, permeabilized, and incubated with or without rabbit anti-FKBP51. After 
a  second staining  with  anti-rabbit  FITC,  cells  were  analyzed  by flow cytometry.  ABCG2 
marked a subpopulation of melanoma cells. According to ABCG2/SSc parameters, two gates 
were placed, one for ABCG2+ cells (red) and another for ABCG2- cells (blue). The expression 
of  FKBP51 was  measured  in  the  gated  populations in  the  FL1-channel.  Bars  indicate  the 
percentage of FL1-positive events, and the values of mean fluorescence intensity (MFI) are 
also indicated.  (B)  Detection of  FKBP51 by immunohistochemistry.  SAN melanoma cells 
expressing ABCG2 were separated from the whole population by BD FACSaria cell sorting, 
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fixed,  and  subjected  to  the  immunohistochemical  examination  of  FKBP51.  (C)  Effect  of 
FKBP51  depletion  on  IR-induced  apoptosis  of  ABCG2+ melanoma cells.  Flow cytometric 
histograms of the annexin V binding of ABCG2+ melanoma cells gated as in A. Melanoma 
cells from SAN, SK-MEL3,  A375, and G361 cell lines were transfected with NS RNA or 
FKBP51 siRNA and irradiated with 4 Gy IR. After 48 h, cells were harvested and stained with  
ABCG2-PE and annexin V-FITC to measure apoptosis.
In  vivo  targeting  of  FKBP51  radiosensitizes  melanoma 
xenografts
We  confirmed  that  the  downmodulation  of  FKBP51  radiosensitized 
melanoma  in  vivo.  We  produced  human  melanoma  xenografts  in 
imminocompromised mice. To investigate apoptosis in tumor xenografts, the 
activation of caspase-3 was determined by the immunohistochemistry of tumor 
sections  and  western  blot  of  tumor  lysates.  Strong  immunoreactivity  for 
cleaved caspase-3 was found in the tumor tissues from xenografts pretreated 
with  FKBP51  siRNA  before  irradiation.  Only  a  few  apoptotic  cells  were 
detected  in  both  non-irradiated  (Fig.18A)  and  irradiated  (Fig.18B)  non-
silenced  tumors,  in  which  most  of  the  melanocytes  were  viable  and 
considerable  mitotic  activity  was  present.  Few  melanocytes  showing  the 
morphological signs of apoptosis and caspase-3 immunoreactivity were found 
in  non-irradiated  silenced  tumors  (Fig.18C).  In  contrast,  a  prevalence  of 
apoptotic melanocytes with clear caspase-3 immunopositivity was present in 
irradiated silenced tumors (Fig.18D). Western blot confirmed the prominent 
activation of caspase-3 in tumors pretreated with FKBP51 siRNA (Fig.18E). 
These finding confirm in vivo that the double treatment FKBP51 siRNA and 
IR activates apoptosis in melanoma.
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Fig.18. IR-induced apoptosis in tumor xenografts pretreated with FKBP51  
siRNA.  Immunohistochemistry  and  western  blot  assay  of  cleaved  caspase-3  in  tumor 
sections. Tumors were excised 48 h after irradiation. For immunohistochemistry, the avidin-
biotin complex technique was used. Original magnification, x250 (A, B, C); x150 (D). The 
morphology of apoptotic nuclei was indicated by blue arrows; green arrows indicate mitosis. 
Enlarged details of apoptotic nuclei from panel D. (E) Whole tissue lysates prepared from the 
same tumors were run in SDS-PAGE for the western blot assay and cleaved caspase3 levels 
were analyzed.
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FKBP51 is a marker of malignant melanocytes
 
Specimens  of  cutaneous melanoma from 80 patients  and 10 samples  of 
normal  skin  stored  in  the  archive  of  the  Pathology section  (Department  of 
Biomorphological and Functional Sciences, University Federico II of Naples, 
Italy)  were  examined  for  FKBP51  expression.  In  normal  skin,  no 
immunopositive melanocytes were found. Table 1 presents the patient profiles 
relative  to  the  cases  studied.  In  most  patients  (58/80,  72%),  a  low  (+) 
immunopositivity was found in melanocytes during the radial growth phase. 
Melanocytes  in  the  vertical  growth  phase  displayed  a  stronger 
immunopositivity (++) compared with radial melanocytes (P<0.001, Pearson 
2 = 62.082). A significant correlation was found between FKBP51 expression 
and  the  thickness  of  the  tumor  lesion  (Spearman’s  =0.646,  P<0.001). 
Moreover,  metastatic  melanoma  was  associated  with  the  highest 
immunoreactivity (+++) (Spearman’s =0.538, P<0.001).
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Case Age 
(y)
Sex Breslow FKBP51r FKBP51v Follow up (y)
1 58 F <1.00 + + 12
2 36 M <1.00 + + 12
3 67 M <1.00 + + 12
4 45 F <1.00 + + 12
5 50 F <1.00 ++ ++ 11
6 49 F <1.00 + + 11
7 42 M <1.00 + + 10
8 43 F <1.00 + + 9
9 43 M <1.00 + ++ 9
10 49 M <1.00 + + 7
11 40 M <1.00 ++ ++ 7
12 41 M <1.00 + + 7
13 39 M <1.00 + ++ 6R
14 37 F <1.00 + + 6
15 66 F 1.01-2.00 ++ ++ 12N
16 65 F 1.01-2.00 + ++ 12
17 56 M 1.01-2.00 + ++ 12
18 49 M 1.01-2.00 + ++ 12
19 48 M 1.01-2.00 + ++ 12
20 39 F 1.01-2.00 + ++ 12
21 47 F 1.01-2.00 ++ +++ 12N,M,D
22 51 M 1.01-2.00 + ++ 11
23 53 M 1.01-2.00 + ++ 11
24 56 M 1.01-2.00 + ++ 11
25 51 F 1.01-2.00 ++ ++ 10
26 45 F 1.01-2.00 + ++ 10
27 53 M 1.01-2.00 + ++ 10
28 67 M 1.01-2.00 + ++ 10
29 54 M 1.01-2.00 + ++ 10
30 34 M 1.01-2.00 + ++ 9
31 44 F 1.01-2.00 + ++ 9
32 43 F 1.01-2.00 + ++ 9
33 71 F 1.01-2.00 ++ +++ 9
34 34 M 1.01-2.00 ++ ++ 9
35 43 F 1.01-2.00 + ++ 9
36 51 F 1.01-2.00 + ++ 9
37 50 M 1.01-2.00 + ++ 9
38 39 F 1.01-2.00 + ++ 9N
39 29 F 1.01-2.00 + ++ 9
40 42 M 1.01-2.00 + ++ 7
41 37 F 1.01-2.00 ++ ++ 7R,N
42 65 M 1.01-2.00 + ++ 7
43 43 M 1.01-2.00 ++ ++ 7N
44 44 F 1.01-2.00 + ++ 6
45 18 F 1.01-2.00 + ++ 4
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Table 1. FKBP51 expression in cutaneous malignant melanoma (CMM) and patients’ profiles.
46 22 M 1.01-2.00 + ++ 4
47 24 M 1.01-2.00 + ++ 4
48 32 M 1.01-2.00 ++ ++ 4
49 30 F 1.01-2.00 + ++ 4
50 38 F 1.01-2.00 + ++ 4
51 37 M 1.01-2.00 + ++ 3
52 40 M 1.01-2.00 + ++ 3
53 40 M 2.01-4.00 ++ +++ 12
54 36 M 2.01-4.00 + ++ 12
55 39 M 2.01-4.00 + ++ 11
56 50 F 2.01-4.00 + +++ 11
57 48 F 2.01-4.00 ++ ++ 11
58 45 M 2.01-4.00 ++ +++ 11N,M,D
59 43 F 2.01-4.00 + ++ 10
60 53 F 2.01-4.00 + ++ 10
61 47 M 2.01-4.00 ++ +++ 10N
62 54 M 2.01-4.00 ++ +++ 10
63 50 M 2.01-4.00 + ++ 10
64 69 F 2.01-4.00 + ++ 10
65 54 M 2.01-4.00 + ++ 10
66 53 M 2.01-4.00 + ++ 9
67 42 F 2.01-4.00 ++ +++ 9N,M,D
68 37 F 2.01-4.00 ++ ++ 9N,M
69 45 F 2.01-4.00 + ++ 9
70 49 F 2.01-4.00 ++ +++ 9N,M,D
71 32 M 2.01-4.00 + ++ 7N
72 38 F 2.01-4.00 + ++ 6N
73 38 M 2.01-4.00 + ++ 3
74 32 M 2.01-4.00 ++ +++ 3N,M
75 40 M 2.01-4.00 ++ +++ 3
76 46 F 2.01-4.00 ++ +++ 3N
77 50 M 2.01-4.00 + ++ 2
78 24 F 2.01-4.00 + ++ 2
79 30 M 2.01-4.00 ++ ++ 2
80 32 F 2.01-4.00 + ++ 2
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FKBP51r, FKBP51 radial growth; FKBP51v, FKBP51 vertical growth; R, recidivation; N, lymph 
node; M, metastasis; D, tumor death.
Figure 19 shows representative immunohistochemical  stains for FKBP51 in 
skin specimens from patients with primitive and metastatic lesions. A definite 
brown cytoplasmic immunostaining for FKBP51 is visible in tumor, but not 
normal, melanocytes. The immunoreactivity of the metastatic cutaneous lesion 
was impressive. In conclusion, our findings unequivocally show that FKBP51 
is  overexpressed  in  melanoma  lesions  of  all  the  patients  studied  and  that 
FKBP51 expression correlates  with  malignity of  the  lesions.  Data obtained 
from this study on 80 melanoma patients reinforce the translational implication 
our previous findings. The relevant data from this analysis is that FKBP51 i) 
was  expressed  in  all  cutaneous  malignant  melanomas  analyzed  but  not  in 
normal  skin;  ii)  expression  was  higher  in  melanocytes  during  the  vertical 
growth phase compared to the radial growth phase; iii) expression correlated 
with  the  thickness  of  the  tumor  lesion;  iv)  expression  was  maximal  in 
metastatic melanoma.
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Fig.19.  FKBP51  expression  in  normal  skin  and  cutaneous  malignant  
melanoma  (CMM).  FKBP51  immunochemical  staining  of  normal  skin  (red  arrows 
indicate  melanocytes,  original  magnification,  x200);  primary  malignant  melanoma spindle 
cells  (original  magnification,  x250);  primary  malignant  melanoma  epithelioid  cells 
(magnification,  x250);  and  dermal  metastasis  from  malignant  melanoma  (original 
magnification, x150), using the avidin–biotin complex technique.
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FKBP51 is a possible novel tumoral marker
Data provided so far support the  conclusion that FKBP51, a protein with 
important biological roles in normal cells (Sinars CR et al. 2003; Bouwmeester 
T et al.  2004; Baughman G et al.  1995), acquires a pro-oncogenic potential 
when its expression is deregulated, which is what occurs in melanoma. Such 
deregulation might sustain survival networks that protect the melanoma against 
killing. Therefore we asked if FKBP51 could play a role in tumor progression 
of other cancers. We performed an immunohistochemistry study of expression 
of  FKBP51 in  fifty  tumoral  samples,  acquired  from our  pathology section, 
including  breast,  lung,  pancreas,  ovary,  and  prostate  (10  samples  for  each 
tumor), and a comparable number of normal tissue samples. At the same time, 
a quantitative measure of FKBP51 mRNA was performed in RNAs exctracted 
by deparaffinized tissues. An intense FKBP51 signal was found in 38 out of 50 
tumors  analyzed,  whereas  normal  tissues  of  the  same  histotypes  showed  a 
weak/absent  immunohistochemical  signal.  The  12  tumor  samples  with 
low/negative immunohistochemistry were the 10 breast cancer samples and 2 
out  of  10  pancreatic  tumors.  Interestingly,  these  two  pancreatic  tumors 
belonged  to  the  well-differentiated  histotype  (G1).  Figure  20A  shows 
representative  immunohistochemical  findings.  Measurement  of  FKBP51 
mRNA levels  in  deparaffinized  tissues  using  real-time  PCR confirmed  the 
immunohistochemistry results (Fig.20B). 
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Fig.20. FKBP51 immunochemical staining of normal and neoplastic tissues.  
(A) FKBP51 immunochemical staining of different tumoral tissues and normal counterpart, 
using the avidin–biotin complex technique. Hematoxylin was used for nuclear counterstaining. 
(B)  Normalized  expression  rates  of  FKBP51  mRNA  (a.u.,  arbitrary  units)  in  PBL  and 
deparaffinized tissues; each histogram is referred to a representative normal or tumoral sample. 
Values represent means and standard deviations of arbitrary units from three different real-
time experiments, each performed in triplicate. The values of each sample were compared to 
PBL (expression=1) for an estimate of the relative expression change fold of FKBP51.
Moreover,  we  performed  a  wide  immunohistochemistry  study  of  FKBP51 
expression  in  21  colon  tumoral  samples.  FKBP51  was  found expressed  in 
normal  colonic  mucosa,  particularly  in  proliferative  basal  zone  of  normal 
glands. An increased expression of the protein was found in 15 out of 21 tumor 
analyzed (Fig.21A). Interestingly,  FKBP51 cellular compartimentalization in 
colon carcinoma changed with grading. FKBP51 was mostly cytosolic in well-
differentiated  colon cancer  (G1),  whereas it  was nuclear  in  undifferentiated 
histotype  (G3)  (Fig.21B).  Immunohistochemistry  data  were  confirmed  by 
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Realtime-PCR. FKBP51 mRNA transcription rates were found higher in colon 
cancer, compared to normal colon (Fig.21C). Taken together, these findings 
suggest that FKBP51 plays a relevant role in cancer biology and can become in 
the near future a novel tumor biomarker.
Fig.21. FKBP51 immunochemical staining of normal and neoplastic colon  
tissue. (A) FKBP51 immunochemical staining of 21 colon tumoral and normal tissues, using 
the avidin–biotin complex technique.  Hematoxylin was used for nuclear counterstaining. (B) 
FKBP51 compartimentalization in colon cancer.  FKBP51 cellular  compartimentalization in 
colon carcinoma changed with grading. FKBP51 was mostly cytosolic in G1 (yellow), whereas 
it was nuclear in G3 (blu) and both nuclear and cytoplasmic in G2 (green). (C) Normalized 
expression  rates  of  FKBP51  mRNA (a.u.,  arbitrary  units)  in  colon  deparaffinized  tissues. 
Values  represent  median  of  arbitrary  units  from  different  real-time  experiments,  each 
performed in triplicate. 
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CONCLUSIONS
Among  cancers,  malignant  melanoma  is  one  of  the  most  resistant  to 
treatment. Patients diagnosed with advanced stage melanoma have a very poor 
prognosis and relatively few treatment options. Given the rising incidence of 
melanoma  and  the  paucity  of  effective  treatments,  there  is  much  hope  for 
targeted therapies and promising agents, including those that act on apoptosis 
regulating molecules. Herein, we showed a novel role for FKBP51 as a marker 
of melanocyte malignancy and its involvement in the protection of melanoma 
against  IR-induced  apoptosis.  Our  data  showed  that  FKBP51  counteracts 
apoptotic processes stimulated by IR by sustaining autophagy, which supports 
the survival of the tumor cells. FKBP51 is required for NF-B activation; in 
fact, FKBP51 silencing prevented the IR-induced nuclear translocation of this 
transcription factor and activated apoptosis. FKBP51 knocking-down provoked 
extensive apoptosis also in vivo, as showed by the study of tumor sections from 
melanoma  xenografts.  Furthermore,  we  provide  evidence  that  FKBP51  is 
espressed at high levels in cancer stem/initiating cell of melanoma and that 
also these cells are killed by IR, after pretreatment with siRNA. This finding 
suggests that FKBP51 is a suitable target for eliminating such cells responsible 
for  tumor  self-renewal  and  generate  the  heterogeneous  cancer  cells  that 
comprise  the  tumor.  The  translational  implication  of  our  findings  was 
reinforced by the correlation of FKBP51 expression levels with the thickness 
of the tumor lesion and with prognostic factors. 
FKBP51  is  a  protein  with  important  biological  roles  in  normal  cells  that 
acquires a pro-oncogenic potential when its expression is deregulated, which is 
what occurs in melanoma. Such deregulation sustains survival networks that 
protect the melanoma against killing. Besides melanoma, FKBP51 is expressed 
in several other cancers; this opens the door to the development of a novel 
tumoral biomarker.
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2Abstract
FK506 binding proteins (FKBPs) are the intracellular ligands of FK506 and rapamycin, two natural
compounds with powerful and clinically efficient immunosuppressive activity. In recent decades, a
relevant role for immunosuppressants as anticancer agents has emerged. Especially, rapamycin and its
derivatives are used, with successful results, across a variety of tumors. Of note, rapamycin and FK506
bind to FKBP12, and the resulting complexes interfere with distinct intracellular signaling pathways
driven, respectively, by the mammalian target of rapamycin and calcineurin phosphatase. These
pathways are related to T-cell activation and growth. Hyperactivation of the mammalian target of
rapamycin (mTOR), particularly in cancers that have lost the tumor suppressor gene PTEN, plays an
important pathogenetic role in tumor transformation and growth. The signaling pathway involving
calcineurin and nuclear factors of activated T-lymphocytes is also involved in the pathogenesis of
different cancer types and in tumor metastasis, providing a rationale for use of FK506 in anticancer
therapy. Recent studies have focused on FKBPs in apoptosis regulation: Targeting of FKBP12
promotes apoptosis in chronic lymphocytic leukemia, FKBP38 knockdown sensitizes hepatoma cells to
apoptosis, and FKBP51 silencing overcomes resistance to apoptosis in acute lymphoblastic leukemia,
prostate cancer, melanoma, and glioma. Interestingly, derivatives of FK506 that have the same
FKBP12-binding properties as FK506 but lack functional immunosuppressant activity, exert the same
apoptotic effect as FK506 in chronic lymphocytic leukemia. These findings suggest that a direct FKBP
inhibition represents a further mechanism of immunosuppressants’ anticancer activity. In this review,
we focus on the role of FKBP members in apoptosis control and summarize the data on the antitumor
effect of selective targeting of FKBP.
Keywords: apoptosis, Bcl-2, cancer, FKBP, NF-κB, targeted therapy, TGF-β,
.
3Introduction
FKBPs and cyclophilins are the two major subfamilies of immunophilins [1]. Immunophilins are
highly conserved proteins endowed with peptidyl-prolyl cis-trans isomerase activity (PPIase), found in
abundance in virtually all organisms [1]. The designation “immunophilin” refers to the
immunosuppressive character of ligand–protein complexes [2]. Cyclosporine is the natural ligand that
binds to cyclophilin A [1], and FK506 and rapamycin are the canonical ligands of FKBPs [1]. FKBP12
is the prototype FKBP [3,4], containing only a single FK506-binding domain (FKBD) comprising 108
amino acids. Human FKBP12 interacts with FK506 and rapamycin with a KD of 0.4 nM and 0.2 nM,
respectively [1, 2, 5]. The complex formations of FKBP with the ligands enhance the stability of
FKBP, and the resulting complexes remain more resistant to proteolytic cleavage and create an
appropriate binding surface for binding to calcineurin (CaN) and the mammalian target of rapamycin
(mTOR) [1, 2, 5]. The FK506/FKBP12 complex interacts with CaN [6] and inhibits its
serine–threonine phosphatase, which is important for activating nuclear factors of activated T-
lymphocytes [7]. In response to antigenic stimuli, this transcription factor stimulates production of
interleukin 2 and other cytokines essential for immune activation [7] .  By contrast, the
rapamycin/FKBP12 complex inhibits the serine–threonine kinase mTOR [8, 9], which is activated in
response to growth factors and nutrients to promote cell-cycle progression [10]. Ultimately, FK506
inhibits the immune response by blocking production of growth factors essential for T-cell clonal
expansion, whereas rapamycin suppresses growth factor–induced T-cell proliferation [6]. Both CaN
[11, 12] and mTOR [10, 13, 14] are deregulated in various cancer types [10-14] and are responsible for
competitive growth advantage, metastatic competence, and therapy resistance, thus providing a
rationale for the use of immunosuppressants against cancer [11-17].
FKBPs are defined as canonical or non-canonical immunophilins on the basis of their binding
strength to FK506 [2]. Despite an overall structural similarity to that of FKBP12 [18], non-canonical
FKBP has multiple substitutions of the aromatic residues in FKBD that unfavorably influence affinity
for FK506 [18]. In addition to FKBD, FKBPs possess further domains involved in protein–protein
interaction or tetratrico peptide repeat (TPR) motifs, nuclear signaling, calcium binding, protein
trafficking, and ATP/GTP-binding sequences [1,2], explaining the wide variety of cellular functions
these proteins exhibit [1, 2, 19-22].
4Several lines of evidence [23-33] support the concept that FKBP members can regulate
programmed cell death through molecular interaction with partners in apoptotic networks. This review
focuses on the anti-apoptotic properties of some FKBP members, namely FKBP12, FKBP38, and
FKBP51, and summarizes the data that support an antitumor effect of selective targeting of these
FKBPs.
Roles of FK506 Binding Proteins in Apoptosis Inhibition
FKBP12 is the guardian of transforming growth factor-β (TGF-β) receptor signaling [22]. TGF-β is a
pleiotropic cytokine that regulates a wide range of biological processes [34-36] and that can transduce
apoptosis by a mitochondria-dependent pathway [36-38]. In particular, TGF-β is apoptotic for
hematopoietic cells and regulates the life span of lymphocytes [39]. The loss of sensitivity to TGF-β
promotes leukemic transformation [40, 41]. FKBP12 acts as a natural ligand for the TGF-β type I
receptor (TβR-I) [22], binding to a glycine- and serine-rich motif (GS motif) of TβR-I, capping its
phosphorylation and stabilizing the inactive conformation of TβR-I [22]. The PPIase core domain of
FKBP12 is important for the interaction of the immunophilin with TβR-I. FK506 inhibits this
interaction and promotes receptor transautophosphorylation [22, 42]. FK506 activates apoptosis of
normal and leukemic lymphocytes through the TGF-β signal [31]. FK506-induced cell death is
preceded by: (i) increased levels of phosphorylated Smad2; (ii) translocation of Smad complexes in the
nucleus; (iii) induction of the death-associated protein (DAP) kinase, a transcriptional target of Smad;
(iv) increased levels of all three Bim isoforms, BimEL, BimL, and BimS and of the Bcl-2–modifying
factor (Bmf); (v) loss of mitochondrial membrane potential; and (vi) caspase 3 activation [31]. The
same apoptotic effect is produced by knocking down FKBP12 [31]. Figure 1 shows a schematic
representation of the TGF-β signaling pathway leading to apoptosis and the role of FKBP12 in the
control of activation of such a signal.
The non-canonical FKBP38 helps the anti-apoptotic protein Bcl-2 to localize at the mitochondrial
membrane and protects cells from apoptosis [23]. FKBP38 interacts with Bcl-2 by binding to the
flexible loop of Bcl-2, between Bcl-2 homology 3 and 4 (BH3 and BH4) regions and protects Bcl-2
from degradation [23]. When FKBP38 is knocked down by siRNA, the level of Bcl-2 protein is
significantly reduced. Interaction of presenilins (PS) with FKBP38 also results in decreased
mitochondrial Bcl-2 and increased susceptibility to apoptosis by antagonizing the anti-apoptotic
5function of FKBP38 [26]. PS1/2 molecules are multipass transmembrane proteins localized
predominantly in the endoplasmic reticulum and Golgi apparatus [43] and are causative agents in
familial Alzheimer's disease [44]. PS1/2 and FKBP38 form macromolecular complexes together with
Bcl-2 [26]. PS1/2 proteins sequester FKBP38 and Bcl-2 in the endoplasmic reticulum/Golgi
compartments, thereby inhibiting FKBP38-mediated mitochondrial targeting of Bcl-2 and promoting
the degradation of FKBP38 and Bcl-2 [26]. Thus, competition between PS1/2 and FKBP38 for
subcellular targeting of Bcl-2 regulates mitochondrially mediated apoptosis. Excessive pro-apoptotic
activity of PS1/2 through this mechanism is thought to explain its role in the pathogenesis of familial
Alzheimer's disease [26,44].
Studies in human fetal liver also confirm the anti-apoptotic role of FKBP38 [27]. The interaction
between the hepatitis C virus (HCV) non-structural protein NS5A and FKBP38 is an important
mechanism for HCV-infected liver cells to evade apoptosis. NS5A contains three BH domains and
mimics the anti-apoptotic function of Bcl-2 [27]. This interaction has been mapped to amino acids
148–236 of NS5A containing a BH domain [27].
The high-molecular-weight FKBP51 is a protein with a specialized role during cell division,
exhibiting preferential expression in mitotically active cells [45-47]. The FKBP51-mediated anti-
apoptotic mechanism involves activation of the NF-κB transcription complex [24, 25, 28-30]. Of note,
NF-κB induces resistance to cancer therapies by modulating the regulation of various anti-apoptotic
genes [48], including inhibitors of apoptosis (IAPs) [49], caspase 8 inhibitory protein (cFLIP) [50],
A1/Bfl1 [51], tumor necrosis factor (TNF) receptor–associated factors 1 and 2 [52], and others [48]. A
proteomic study of mapping of the TNFα/NF-κB signal transduction pathway [53] first identified
FKBP51 as an IKKα co-factor, essential for the function of the IKK kinase complex. Subsequent
studies [24, 25, 33] from our group also showed that FKBP51 controls NF-κB activation by DNA-
damaging agents, including anthracyclin compounds [24, 25] and ionizing radiation [33]. As Figure 2A
shows, FKBP51 physically interacts with IKK following treatment of tumor cell with ionizing
radiation. This interaction plays a crucial role in the activation of IKK kinase, as suggested by the lack
of increase in phospho-IκBα levels after irradiation of FKBP51-depleted cells (Figure 2B). As is
already established, IκB phosphorylation, followed by proteolytic degradation of inhibitors, controls
cytoplasmic shuttling to the nucleus of NF-κB dimers in response to cell stimulation [23, 24]. FKBP51
plays a relevant role in counteracting apoptotic processes stimulated by radio- and chemotherapy.
6Targeting of FKBP51 counteracts NF-κB activation and efficiently overcomes blockage of the
apoptotic machinery provoked by this transcription factor, thus permitting cell death [24, 25, 28, 29,
33]. Hyperexpression of the RelA subunit of the NF-κB complex counteracts the pro-apoptotic effect
of FKBP51 knockdown [25].
Targeting of FKBP in Cancer
Targeting of FKBP12 with FK506 or siRNA increases TGF-β signaling and stimulates apoptosis of
chronic lymphocytic leukemia (CLL) cells [31]. The apoptotic effect of FK506 occurs regardless of the
immunosuppressive mechanism [31]. Derivatives of FK506 that have the same FKBP12-binding
properties as FK506 but lack the calcineurin binding capability, and thus lack functional
immunosuppressant activity, are expected to exert the same pro-apoptotic effect as FK506 in CLL.
Consistent with this hypothesis, we showed that three FK506 analogs, FK520, 15-O-demethyl-FK520,
and 18-OH-FK520, induce CLL cell death to the same extent as FK506 (Fig. 3). 15-O-demethyl-
FK520 and 18-OH-FK520, although bind to FKBP12, have modifications in the composite calcineurin
binding surface, thereby display a reduced CaN inhibitory effect compared to FK506 [54, 55]. There is
growing interest in therapeutically targeting TGF-β–mediated processes in cancer [56-59], including
hematological malignancies [60]. TGF-β, although involved in metastatic processes in advanced
tumors, acts as an early tumor suppressor [61]. Loss of response to TGF-β is thought to contribute to
tumorigenesis [35, 36, 40, 41] and drug resistance of tumor cells [62]. Targeting of FKBP12 may
represent a strategy in cancer chemoprevention or a therapy for early-stage tumors [59].
HCV infection often leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma [63].
A defect of apoptosis, resulting from viral protective strategies, significantly contributes to persistent
HCV infection [64] and works together with chronic inflammation [65] to cause tumor transformation.
NS5A represents one of these viral anti-apoptotic strategies in HCV infection [27]. Targeting of
FKBP38 using RNA interference specifically abrogates resistance to apoptosis of hepatoma cells that
hyperexpress the HCV protein NS5A [27]. These results suggest that targeting of FKBP38 may be
beneficial in HCV-associated hepatocellular carcinoma.
Targeting of FKBP51 with rapamycin or siRNA sensitizes poor-responsive human melanoma
cells to anthracyclin-triggered apoptosis by antagonizing the induction of the anti-apoptotic genes Bcl-
2 and c-IAP1 under NF-κB transcriptional control [24]. In addition, FKBP51 targeting enhances the
7cytotoxic effect of ionizing radiation in the same tumor [33]. Of greater interest, FKBP51 is expressed
at high levels in melanoma cancer stem/initiating cells [33]. These cells are recognizable by the
presence of surface markers, including the ATP-binding cassette transporters ABCB5 and ABCG2
[66]. Apparently, melanoma cancer stem cells are killed by ionizing radiation after pre-treatment with
FKBP51 siRNA [33], suggesting that FKBP51 may be a suitable target for eliminating such cells
responsible for self renewal and recurrence of the tumor. The efficacy of FKBP51 targeting against
melanoma has also been documented in vivo in a melanoma xenograft mouse model [33]. In addition,
targeting of FKBP51 is associated with enhanced apoptosis and reduced proliferation in gliomas [30].
In acute lymphoblastic leukemia, inhibition of FKBP51 overcomes resistance to anthracyclin
compounds [25]. In prostate cancer, targeting of FKBP51 dramatically decreases androgen receptor
transcriptional activity and tumor growth [32].
Conclusion
FKBPs perform multiple biological functions through specific protein–protein interactions and by
acting as chaperones [1, 2]. The molecular interaction with receptors [31, 32], kinases [24, 25, 28, 33],
or other proteins [23, 26, 27] that take part in apoptotic signaling cascades also implicates members of
this protein family in regulation of programmed cell death [23-33]. Apoptosis plays a crucial role in the
control of tissue homeostasis, and defective cell death mechanisms are known to lead to cancer [67].
Furthermore, most cytotoxic anticancer agents induce apoptosis, thus raising the possibility that defects
in apoptotic programs contribute to treatment failure [67]. There is much hope for the potential of
signaling therapies against cancer, and a greater understanding of the molecular pathways of apoptosis
and the causes of their malfunction in cancer is expected to provide new therapeutic targets that may
lead to breakthroughs in cancer treatment [68]. Evidence of elevated levels of some FKBP members in
tumors [30, 32, 33, 69-71], together with a clear apoptosis sensitizing effect of FKBP inhibition [23-27,
30-33], point to this class of proteins as possible novel targets for cancer therapy. Further studies on the
role of this class of proteins in apoptosis dysfunction in cancer may open the door in the near future to
developing novel small molecules specifically targeting FKBP. This approach can be achieved by
structural studies of FKBP and its partners in apoptotic processes.
List of abbreviations:
8Bcl-2 B-cell lymphoma 2, BH Bcl-2 homology, CaN calcineurin, CLL chronic lymphocytic leukemia,
FKBP FK506 binding protein, HCV hepatitis C virus, IAP inhibitor of apoptosis, IKK Inhibitor κB
kinase, mTOR  mammalian target of rapamycin, NF-κB nuclear factor of κ light-chain-enhancer of
activated B cells, PS presenilins, TβR-I  transforming growth factor-β type I receptor, TβR-II
transforming growth factor-β type II receptor, TGF-β transforming growth factor-β.
Acknowledgements
We thank the AIRC foundation for supporting our research.
References
[1] Dornan, J.; Taylor, P.; Walkinshaw, M.D. Structures of Immunophilins and their Ligand
Complexes. Curr. Top. Med. Chem., 2003, 3(12), 1392-1409.
[2] Kang, C.B.; Hong, Y.; Dhe-Paganon, S.; Yoon, H.S. FKBP family proteins: immunophilins
with versatile biological functions. Neurosignals, 2008, 16(4), 318-325.
[3] Siekierka, J.J.; Hung, S.H.; Poe, M.; Lin, C.S.; Sigal, N.H. A cytosolic binding protein for the
immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.
Nature, 1989, 341(6244), 755-757.
[4] Standaert, R.F.; Galat, A.; Verdine, G.L.; Schreiber, S.L. Molecular cloning and
overexpression of the human FK506-binding protein FKBP. Nature, 1990, 346(6285), 671-674.
[5] Fischer, G.; Aumüller, T. Regulation of peptide bond cis/trans isomerization by enzyme
catalysis and its implication in physiological processes. Rev. Physiol. Biochem. Pharmacol., 2003, 148,
105-150. Review.
[6] Abraham, R.T.; Wiederrecht, G.J. Immunopharmacology of rapamycin. Annu. Rev.
Immunol., 1996, 14, 483-510.
9[7] Rao, A.; Luo, C.; Hogan, P.G. Transcription factors of the NFAT family: Regulation and
function. Annu. Rev. Immunol., 1997, 15, 707-747.
[8] Sabatini, D.M.; Erdjument-Bromage, H.; Lui, M.; Tempst, P.; Snyder, S.H. RAFT1: a
mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to
yeast TORs. Cell, 1994, 78, 35-43.
[9] Choi, J.; Chen, J.; Schreiber, S.L.; Clardy, J. Structure of the FKBP12-rapamycin complex
interacting with the binding domain of human FRAP. Science, 1996, 273(5272), 239-42.
[10] Schmelzle, T.; Hall, M.N. TOR, a central controller of cell growth. Cell, 2000, 103(2), 253-
262.
[11] Jauliac, S.; López-Rodriguez, C.; Shaw, L.M.; Brown, L.F.; Rao, A., Toker, A. The role of
NFAT transcription factors in integrin-mediated carcinoma invasion. Nat. Cell. Biol., 2002, 4(7), 540-
544.
[12] Müller, M.R.; Rao, A. Linking calcineurin activity to leukemogenesis. Nat. Med., 2007, 13(6),
669-671.
[13] Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT
pathway for cancer drug discovery. Nat. Rev. Drug. Disc., 2005, 4(12), 988-1004.
[14] Bjornsti, M.A.; Houghton, P.J. The Tor pathway: a target for cancer therapy. Nat. Canc. Rev.,
2004, 4, 335-348. 
[15] Neshat, M.S.; Mellinghoff, I.K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.;
Gibbons, J.J.; Wu, H.; Sawyers, C.L. Sensitivity of PTEN-deficient tumors to inhibition of
FRAP/mTOR. Proc. Natl. Acad. Sci. USA., 2001, 98(18), 10314-10319.
10
[16] Siamakpour-Reihani, S.; Bandhu-Nepal, D.; Courtwright, A.; Hilliard, E.; Ketelsen, D.;
Patterson, C.; Klauber-DeMore N. The calcineurin inhibitor tacrolimus inhibits breast tumor growth in
vivo. Cancer Res., 2009, 69 (24 Suppl), Abstract nr 3170.
[17] Neshat, M.S.; Mellinghoff, I.K.; Tran, C.; Stiles, B.; Thomas, G.; Petersen, R.; Frost, P.;
Gibbons, J.J.; Wu, H.; Sawyers, C.L. Sensitivity of PTEN-deficient tumors to inhibition of
FRAP/mTOR. Proc. Natl. Acad. Sci. USA., 2001, 98(18), 10314-10319.
[18] Maestre-Martínez, M.; Edlich, F.; Jarczowski, F.; Weiwad, M.; Fischer, G.; Lücke, C.
Solution structure of the FK506-binding domain of human FKBP38. J. Biomol. NMR., 2006, 34(3),
197-202.
[19] Cameron, A.M.; Steiner, J.P.; Sabatini, D.M.; Kaplin, A.I.; Walensky, L.D.; Snyder, S.H.
Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates
calcium flux. Proc. Natl. Acad. Sci. USA., 1995, 92(5), 1784-1788.
[20] Lu, K.P.; Finn, G.; Lee, T.H.; Nicholson, L.K. Prolyl cis-trans isomerization as a molecular
timer. Nat. Chem. Biol., 2007, 3(10), 619-629.
[21] Nelson, C.J.; Santos-Rosa, H.; Kouzarides, T. Proline isomerization of histone H3 regulates
lysine methylation and gene expression. Cell, 2006, 126(5), 905-916.
[22] Wang, T.; Li, B.Y.; Danielson, P.D.; Shah, P.C.; Rockwell, S.; Lechleider, R.J.; Martin, J.;
Manganaro, T.; Donahoe, P.K. The immunophilin FKBP12 functions as a common inhibitor of the
TGF beta family type I receptors. Cell, 1996, 86(3), 435-44.
[23] Shirane, M.; Nakayama, K.I. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to
mitochondria and inhibits apoptosis. Nat. Cell. Biol., 2003, 5(1), 28-37.
11
[24] Romano, M.F.; Avellino, R.; Petrella, A.; Bisogni, R.; Romano, S.; Venuta, S. Rapamycin
inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma
cells. Eur. J. Cancer. 2004, 40(18), 2829-2836.
[25] Avellino, R.; Romano, S.; Parasole, R.; Bisogni, R; Lamberti, A.; Poggi, V.; Venuta, S.;
Romano, M.F. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells.
Blood, 2005, 106(4), 1400-1406.
[26] Wang, H.Q.; Nakaya, Y.; Du, Z.; Yamane, T.; Shirane, M.; Kudo, T.; Takeda, M.;
Takebayashi, K.; Noda, Y.; Nakayama, K.I.; Nishimura, M. Interaction of presenilins with FKBP38
promotes apoptosis by reducing mitochondrial Bcl-2. Hum. Mol. Genet., 2005, 14(13), 1889-1902.
[27] Wang, J.; Tong, W.; Zhang, X.; Chen, L.; Yi, Z.; Pan, T.; Hu, Y.; Xiang, L.; Yuan, Z.
Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in
hepatoma cells. FEBS Lett., 2006, 580(18), 4392-4400.
[28] Giordano, A.; Avellino, R.; Ferraro, P.; Romano, S.; Corcione, N.; Romano, M.F. Rapamycin
antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth
muscle cells and enhances apoptosis. Am. J. Physiol. Heart. Circ. Physiol., 2006, 290(6), H2459-65.
[29] Romano, M.F.; Romano, S.; Mallardo, M.; Bisogni, R.; Venuta, S. In: Rapamycin controls
multiple signalling pathways involved in cancer cell survival. Cell Apoptosis Research Trends. Nova
Publishers, ED.; 2007, 263-276, 40(18), 2829-2836.
[30] Jiang, W.; Cazacu, S.; Xiang, C.; Zenklusen, J.C.; Fine, H.A.; Berens, M.; Armstrong, B.;
Brodie, C.; Mikkelsen, T. FK506 binding protein mediates glioma cell growth and sensitivity to
rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia, 2008, 10(3), 235-243.
12
[31] Romano, S.; Mallardo, M.; Chiurazzi, F.; Bisogni, R.; D'Angelillo, A.; Liuzzi, R.; Compare,
G.; Romano, M.F. The effect of FK506 on transforming growth factor beta signaling and apoptosis in
chronic lymphocytic leukemia B cells. Haematologica, 2008, 93(7), 1039-1048.
[32] Periyasamy, S.; Hinds, T.Jr.; Shemshedini, L.; Shou, W.; Sanchez, E.R. FKBP51 and Cyp40
are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and
cyclosporin A. Oncogene, 2010, 29(11), 1691-1701.
[33] Romano, S.; D'Angelillo, A.; Pacelli, R.; Staibano, S.; De Luna, E.; Bisogni, R.; Eskelinen,
E.L.; Mascolo, M.; Calì, G.; Arra, C.; Romano, M.F. Role of FK506-binding protein 51 in the control
of apoptosis of irradiated melanoma cells. Cell. Death. Differ. 2010, 17(1), 145-57.
[34] Massague, J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell. Biol., 2000, 1(3), 169-
178. Review.
[35] Massague, J.; Blain, S.W. TGF beta signaling in growth control, cancer, and heritable
disorders. Cell, 2000, 103, 295-309. Review.
[36] Siegel, P.M.; Massague, J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and
cancer. Nat. Rev. Cancer., 2005, 3(11), 807-821. Review.
[37] Jang, C.W.; Chen, C.H.; Chen, C.C.; Chen, J.Y.; Su, Y.H.; Chen, R.H. TGF-beta induces
apoptosis through Smad-mediated expression of DAP-kinase. Nat. Cell. Biol., 2001, 4(1), 51-58.
[38] Perlman, R.; Schiemann, W.P.; Brooks, M.W.; Lodish, H.F.; Weinberg, R.A. TGF-beta-
induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat. Cell.
Biol., 2001, 3(8), 708-714.
13
[39] Chaouchi, N.; Arvanitakis, L.; Auffredou, M.T.; Blanchard, D.A.; Vazquez, A.; Sharma, S.
Characterization of transforming growth factor-beta 1 induced apoptosis in normal human B cells and
lymphoma B cell lines. Oncogene, 1995, 11(8), 1615-1622.
[40] Lucas, P.J.; McNeil, N.; Hilgenfeld, E.; Choudhury, B.; Kim, S.J.; Eckhaus, M.A.; Ried, T.;
Gress, R.E. Transforming growth factor-beta pathway serves as a primary tumor suppressor in CD8+ T
cell tumorigenesis. Cancer Res., 2004, 64(18), 6524-6529.
[41] Wolfraim, L.A.; Fernandez, T.M.; Mamura, M.; Fuller, W.L.; Kumar, R.; Cole, D.E.; Byfield,
S.; Felici, A.; Flanders, K.C.; Walz, T.M.; Roberts, A.B.; Aplan, P.D.; Balis, F.M.; Letterio, J.J. Loss
of Smad3 in acute T-cell lymphoblastic leukemia N. Engl. J. Med., 2004, 351(6), 552-559.
[42] Chen, Y.G.; Liu, F.; Massague, J. Mechanism of TGFbeta receptor inhibition by FKBP12.
EMBO J., 1997, 16(13), 3866-3876.
[43] Li, X.; Greenwald, I. Membrane Topology of the C. elegans SEL-12 Presenilin. Neuron, 1996,
17(5), 1015-1021.
[44] St. George-Hyslop, P.H. Molecular genetics of Alzheimer's disease. Biol. Psychiatry, 47(3),
183-199.
[45] Liu, T.M.; Martina, M.; Hutmacher, D.W.; Hui, J.H.; Lee, E.H.; Lim, B. Identification of
common pathways mediating differentiation of bone marrow- and adipose tissue-derived human
mesenchymal stem cells into three mesenchymal lineages. Stem cells, 2007, 25(3), 750-760.
[46] Menicanin, D.; Bartold, P.M.; Zannettino, A.C.; Gronthos, S. Genomic profiling of
mesenchymal stem cells. Stem Cell Rev., 2009, 5(1), 36-50. Review.
14
[47] Yeh, W.C.; Li, T.K.; Bierer, B.E. McKnight, S.L. Identification and characterization of an
immunophilin expressed during the clonal expansion phase of adipocyte differentiation. Proc. Natl.
Acad. Sci. USA., 1995, 92(24), 11081-11085.
[48] Karin, M.; Cao, X.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: from innocent bystander to
major culprit. Nat. Rev. Cancer, 2002, 2(4), 301-310.
[49] Roy, N.; Deveraux, Q.L.; Takahashi, R.; Salvesen, G.S.; Reed, J.C. The c-IAP-1 and c-IAP-2
proteins are direct inhibitors of specific caspases. EMBO J., 1997, 16(23), 6914–6925.
[50] Thome, M.; Schneider, P.; Hofmann, K.; Fickenscher, H.; Meinl, E.; Neipel, F.; Mattmann,
C.; Burns, K.; Bodmer, J.L.; Schroter, M.; Scaffidi, C.; Krammer, P.H.; Peter, M.E.; Tschopp, J. Viral
FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature, 1997,
386(6624), 517-520.
[51] Wang, C.Y.; Guttridge, D.C.; Mayo, M.W.; Baldwin, A.S.Jr. NF-κB Induces Expression of
the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis. Mol.
Cell. Biol., 1999, 19(9), 5923-5929.
[52] Rothe, M.; Wong, S.C.; Henzel, W.J.; Goeddel, D.V. A novel family of putative signal
transducers associated with the cytoplasmic domain fo the 75 kDa tumor necrosis factor receptor. Cell,
1994, 78, 681-692.
[53] Bouwmeester, T.; Bauch, A.; Ruffner, H.; Angrand, P.O.; Bergamini, G.; Croughton, K.;
Cruciat, C.; Eberhard, D.; Gagneur, J.; Ghidelli, S.; Hopf, C.; Huhse, B.; Mangano, R.; Michon, A.M.;
Schirle, M.; Schlegl, J.; Schwab, M.; Stein, M.A.; Bauer, A.; Casari, G.; Drewes, G.; Gavin, A.C.;
Jackson, D.B.; Joberty, G.; Neubauer, G.; Rick, J.; Kuster, B.; Superti-Furga, G. A physical and
functional map of the human TNF-alpha/NF-kappaB signal transduction pathway. Nat. Cell. Biol.,
2004, 6, 97-105.
15
[54] Kawai, M.; Lane, B.C.; Hsieh, G.C.; Mollison, K.W.; Carter, G.W.; Luly, J.R. Structure-
activity profiles of macrolactam immunosuppressant FK-506 analogues. FEBS Lett., 1993, 316(2),
107-113.
[55] Liu, J.; Albers, M.W.; Wandless, T.J.; Luan, S.; Alberg, D.G.; Belshaw, P.J.; Cohen, P.;
MacKintosh, C.; Klee, C.B.; Schreiber, S.L. Inhibition of T cell signaling by immunophilin-ligand
complexes correlates with loss of calcineurin phosphatase activity. Biochemistry, 1992, 31(16), 3896-
3901.
[56] Elliot, R.L.; Blobe, G.C. Role of transforming growth factor-β in human cancer. J. Clin.
Oncol., 2005, 23(9), 2078-2093.
[57] Arteaga, C.L. Inhibition of TGFβ signaling in cancer therapy. Curr. Opin. Genet. Dev., 2006.
16(1), 30-37.
[58] Massagué, J. TGFβ in cancer. Cell, 2008, 134(2), 215-230.
[59] Romano, M.F. Targeting TGFbeta-mediated processes in cancer. Curr. Opin. Drug. Discov.
Devel., 2009, 12(2), 253-63. Review.
[60] Dong, M.; Blobe, G.C. Role of transforming growth factor-beta in hematologic malignancies.
Blood, 2006, 107(12), 4589-4596.
[61] Bierie, B.; Moses, H.L. Tumour microenvironment: TGFβ: The molecular Jekyll and Hyde of
cancer. Nat. Rev. Cancer., 2006, 6(7), 506-520.
[62] Stoika, R.; Yakymovych, M.; Souchelnytskyi, S.; Yakymovych, I. Potential role of
transforming growth factor beta1 in drug resistance of tumor cells. Acta. Biochem. Pol., 2003, 50(2),
497-508.
16
[63] Di Bisceglie, A.M. Hepatitis C. Lancet, 1998, 351(9099), 351-355.
[64] Shimotohno, K. Hepatitis C virus as a causative agent of hepatocellular carcinoma.
Intervirology, 1995, 38(3-4), 162-169.
[65] Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420(6917), 860-867.
[66] Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.M.; Sampath, J.; Morris, J.J.; Lagutina,
I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; Sorrentino, B.P. The ABC transporter Bcrp1/ABCG2 is
expressed in a wide variety of stem cells and is a molecular determinant of the side-population
phenotype. Nat. Med., 2001, 7(9), 1028-1034.
[67] Brown, J.M.; Attardi, L.D. The role of apoptosis in cancer development and treatment
response. Nat. Rev. Cancer., 2005, 5(3), 231-237.
[68] Ghobrial, I.M.; Witzig, T.E.; Adjei, A.A. Targeting Apoptosis Pathways in Cancer Therapy.
Cancer J. Clin., 2005, 55,178-194.
[69] Khatua, S.; Peterson, K.M.; Brown, K.M.; Lawlor, C.; Santi, M.R.; LaFleur, B.; Dressman,
D.; Stephan, D.A.; MacDonald, T.J. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway
identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res., 2003, 63(8), 1865-
1870.
[70] Olesen, S.H.; Christensen, L.L.; Sørensen, F.B.; Cabezón, T.; Laurberg, S.; Orntoft, T.F.;
Birkenkamp-Demtröder, K. Human FK506 binding protein 65 is associated with colorectal cancer.
Mol. Cell. Proteomics., 2005, 4(4), 534-544.
[71] Romano, S.; D'Angelillo, A.; Staibano, S.; Ilardi, G.; Romano, M.F. FK506-binding protein
51 is a possible novel tumoral target. Cell. Death. Dis., 2010, Published online 15 July 2010.
17
Legends to the figures
Fig. 1 Schematic representation of TGF-β signal. (A) TGF-β binds a specific pair of membrane
receptors, type I (TβR1) and type II (TβR2), that contain a cytoplasmic serine–threonine kinase
domain. This binding results in the formation of a TβR1/TβR2 heteromeric complex and activation of
TβR2 kinase. Activated TβR1 specifically recognizes and phosphorylates signaling molecules that act
on downstream receptors, namely R-Smad, which form a complex with other Smad molecules (Co-
Smad). This complex translocates into the nucleus and can activate transcription of genes involved in
mitochondrial apoptosis. (B) Activation of TβR1 requires phosphorylation of the GS (glycine, serine)
region by TβR2. Under basal conditions, this region is capped by FKBP12, blocking the signal
progression. FK506 displaces the immunophilin from the GS region, thus permitting TGF-β signaling
in the absence of ligand. (C) Activation of such a signal can also be achieved by knocking down
FKBP12 with specific siRNA that targets the FKBP12 mRNA, leading to RNA degradation and
reduced protein levels.
Fig. 2 FKBP51 controls ionizing radiation–induced NF-κB activation in melanoma. (A)
FKBP51/IKK interaction in melanoma cells. Whole cell lysates of melanoma SAN cell line [24, 33],
not irradiated and 3 h after irradiation with 4 Gy, were prepared by homogenization in modified RIPA
buffer. After obtaining a homogeneous suspension, protein concentration was determined and 500 µg
of protein extract was precleared for 1 h. For immunoprecipitation, 15 µg anti-FKBP51 or anti-IKKα/β
were added together with 25 µL protein A-Sepharose, and precipitation took place overnight with
rotation at 4°C. Immunoprecipitated and total lysates were then separated by a SDS/polyacrylamide gel
electrophoresis, transferred onto a membrane filter, and incubated with goat polyclonal anti-FKBP51 or
rabbit anti-IKKα/β. The immunoprecipitation assay result, that was confirmed in another independent
experiment, suggests that FKBP51 directly interacts with IKKα/β after exposure to ionizing radiation
(IR), thus activating NF-κB transcriptional factors. (B) Western blot assay of IκBα and phospho-IκBα
levels. At 48 h from transfection, melanoma cells were irradiated at 4 Gy and harvested at the indicated
times. Cytosolic extracts were obtained from melanoma SAN cells transfected with FKBP51 siRNA or
a non silencing (NS) RNA as control, by homogenization in lysing buffer. Cytosolic lysates were then
separated using SDS-PAGE gel and transferred onto a membrane filter that was incubated with rabbit
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polyclonal anti-IKKα/β and anti–phospho-IKKα/β. These results suggest that in irradiated cells,
FKBP51 downmodulation blocks IκBα phosphorylation and degradation, thus avoiding NF-κB
activation.
Fig. 3 Targeting of FKBP12 causes apoptosis of CLL cells. CLL cells, isolated from heparinized
blood, were cultured with FK506, FK520, 15-O-DES-FK520, and 18-OH-FK520 at a dose of 100 nM
and cyclosporine at a dose of 300 nM. After 24 h, cells were harvested, and phosphatidylserine
externalization was investigated by annexin V-FITC staining. Then cells were analyzed by flow
cytometry.  Numbers reported in the dot plots represent the percentages of FITC-positive cells.
Increased annexin V binding was observed in samples cultured with FK506 or its analogs and not with
cyclosporine.



